ISSUED TO M/S. _____

S.No……. ***NOT TRANSFERABLE***

TENDER NO:- BPPI/DRUG - 029/2015

TENDER FOR SUPPLY OF DRUGS & MEDICINES

TO

Bureau of Pharma Public Sector Undertakings of India (BPPI)

For the year 2015-17

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA

(Set up under the Department of Pharmaceuticals, Govt. of India)

IDPL corporate office Complex, Old-Delhi-Gurgaon Road, Dundahera, Gurgaon 122016

Telephone: 0124-4040759 / 4556751; Fax: 0124-2340370 Website: **janaushadhi.gov.in**

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA (BPPI)
(SET UP UNDER THE DEPARTMENT OF PHARMACEUTICALS, GOVERNMENT OF INDIA)
Regd. Office: Core No. 6, First Floor, SCOPE Complex, Lodi Road, New Delhi-110003
Working Office: IDPL CORPORATE OFFICE, IDPL COMPLEX, DUNDAHERA, GURGAON (HR)
Telephone: **0124-4556751/56**; Fax: **0124-2340370** Website: **janaushadhi.gov.in**

TENDER FOR THE SUPPLY OF DRUGS AND MEDICINES TO BUREAU OF PHARMA PSU OF INDIA FOR THE YEAR 2015-2017

Tender Reference		**BPPI/DRUG- 029/2015 Dt. 22.09.2015**
Date of availability of tender documents on website		**22.09.2015 (Tuesday)**
Time and date and place pre-bid meeting		**11:00 AM on 30/09/2015 (Wednesday)** Bureau of Pharma **PSUs** of India, IDPL corporate office, IDPL Complex, Old-Delhi -Gurgaon Road, Dundahera, Gurgaon-122016 (Haryana)
Last date and time for receipt of tender documents		**14/10/2015 upto 12:00 Noon**
Time and date of opening of tender		**12:30 PM on 14/10/2015 (Wednesday)**
Place of opening of tender		Bureau of Pharma PSUs of India, IDPL corporate office Complex, Old-Delhi -Gurgaon Road, Dundahera, Gurgaon- 122016 (Haryana)
Address for Communication		Bureau of Pharma Public Sector Undertakings of India, IDPL corporate office Complex, Old-Delhi -Gurgaon Road, Dundahera, Gurgaon- 122016 (Haryana)
Cost of the Tender Document		**Rs. 2,250/- (Inclusive of Tax)**

Contact Person for clarification if any		**1. Sh. K Chopra,** Director (Operations) Phone:- 0124-4040759/4556751 Mob:- 9711003043 Email: kchopra.bppi@gmail.com
		2. Mrs. Sanyukta Singh, Executive (Procurement) Phone:- 0124-4556764/767 Email:- proc1.bppi@gmail.com

The tender document can be downloaded from the website of BPPI: ***janaushadhi.gov.in*** *and* ***pharmaceuticals.gov.in.*** However the cost of tender form needs to be paid by way of demand draft drawn in any nationalized bank in favor of "Bureau of Pharma Public Sector Undertakings of India "payable at Gurgaon/Delhi along with tender document at the time of submission.

TABLE OF CONTENTS

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA

TENDER FOR THE SUPPLY OF DRUGS AND MEDICINES TO BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA

FOR THE YEAR 2015-17

Jan Aushadhi Scheme is the initiative of Department of Pharmaceuticals, Ministry of Chemical and Fertilizer, Government of India launching with the noble objective of making quality generic medicines available at affordable prices for all, particularly the poor and disadvantaged, through specialized outlets called Jan Aushadhi Stores (JAS). In order to enable a focused and institutional approach to implement the Jan Aushadhi Campaign in particular, BPPI was established in December, 2008 under the Department of Pharmaceuticals, Government of India, with the support of all the CPSUs, and identified as the executing agency for JAS Scheme.

The Bureau has been registered as an independent society under the Societies Registration Act, 1860, in April, 2010. BPPI follows the provisions of GFR, 2005 as amended from time to time, the CVC guidelines, and instructions from the Department of Pharmaceuticals.

After varied success in last five years and to give a new thrust to Jan Aushadhi Campaign, a New Business Plan has been worked out. It aims to extend the geographical coverage of the scheme, by opening more than 3000 stores during the 12^{th} Plan Period. It is proposed to channelize efforts to popularize the scheme in a few selected states and ensure availability of the complete basket of medicines at affordable prices.

Tender Inviting Authority – Director (Operations), Bureau of Pharma Public Sector Undertakings of India, IDPL Corporate Office, IDPL Complex, Old-Delhi-Gurgaon Road, Dundahera, Gurgaon -122016 (Haryana) (hereinafter referred as **Tender Inviting Authority** unless the context otherwise requires).

Tender Accepting Authority – CEO, Bureau of Pharma Public Sector Undertakings of India,(hereinafter referred as **BPPI** unless the context otherwise requires)

Tender Inviting Authority invites **Tender for the supply of Drugs and Medicines to BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA, for the year 2015-2017.**

1. LAST DATE FOR RECEIPT OF TENDERS.

(a) Sealed Tenders [in two separate covers {Technical bid (Cover "A") and price bid Price Bid (Cover "B")}] will be received **till 12:00 Noon upto 14/10/2015(Wednesday)** by the Tender Inviting Authority, Bureau of Pharma Public Sector Undertakings of India, IDPL corporate office, IDPL complex, Old-Delhi-Gurgaon Road, Dundahera, Gurgaon -122016 (Haryana) for the year 2015-17.

(b) The price bid shall be valid for a period of 120 days from the date of opening of Cover-A (Technical Bid). Prior to the expiry of the bid validity, the Tender Inviting Authority may request the Tenderers to extend the bid validity for further period as deemed fit on their original quoted prices and all terms & conditions. However, BPPI reserves the right to place purchase orders at the quoted rate till such period.

2. ELIGIBILITY CRITERIA

(a) Tenderer shall be a manufacturer having valid own drug manufacturing unit duly licensed by licensing authorities with valid GMP certificate/WHO Certificate or direct importer holding valid import license. Distributors/Suppliers/Agents are not eligible to participate in the Tenders. Loan licensees are allowed provided the average annual turnover of bidding company should be at least Rs. 100 Crores for last three years and the average annual turnover of Host Firm (actual manufacturer) should be minimum Rs. 10 crores during the last 3 years.

(b) Average Annual turnover in the last three years i.e. 2012-13, 2013-14 and 2014-15 shall not be less than **Rs. 10 Crores.** For loan licensees, average annual turnover should be at least 100 crores in last 3 years.

(c) Tender should not be submitted for the product(s) for which the firm / company has been blacklisted/debarred/de-registered by any State Government / Central Government / its Drug procurement agencies due to quality failure of the drugs ***at the time of submission of tender documents.***

(d) The Company/Firm which has been blacklisted/debarred/de-registered by any State Government/Central Government / its Drug procurement agencies due to quality failure of the drugs supplied should not participate in the tender during the period of blacklisting/debarred/de-registration at ***the time of submission of tender documents.***

(e) (i) The Tenderer should give a notarized affidavit that they have not been black listed/debarred/de-registered due to quality failure for the quoted product /firm by any State

Government / Central Government / its Drug procurement agencies. (Notarized affidavit as per **ANNEXURE-I**) ***at the time of submission of tender documents.***

(ii) During the validity of the tender if the firm / Company is blacklisted/debarred/de-registered by any State Government / Central Government / its Drug procurement agencies / convicted by any Court of law in India, it shall be intimated to BPPI alongwith relevant authentic document by the tenderer firm/ company within one month.

(f) Tenderers are required to submit undertaking on letterhead by authorised signatory confirming that they have read tender document including Amendment(s) to Tender document (if any) along with terms and condition and these terms and condition of tender document including Amendment(s) to Tender document (if any) are acceptable unconditionally to them.(**ANNEXURE – II).**

3. GENERAL CONDITIONS.

(i) The tender document shall be download from the websites janaushadhi.gov.in; pharmaceuticals.gov.in and CPP portal i.e. eprocure.gov.in. However the cost of tender form (Rs. 2,250/- Inclusive of Tax) needs to be paid by way of demand draft drawn in favor of "Bureau of Pharma Public Sector Undertakings of India" payable at Gurgaon/Delhi along with the tender(**ANNEXURE – III**). In case demand draft towards the cost of tender is not submitted along with tender, their bid shall be rejected straightaway.

(ii) All tenders must be accompanied with Earnest Money Deposit as specified in Clause 7 of the Tender document. The bid received without requisite amount of EMD will be summarily rejected.

(iii) Tenders will be opened in the presence of Tenderers/authorized representatives who choose to attend on the specified date and time. They should bring letter of authority authorising to attend tender opening on the printed letter head of the company.

(iv) (a) At any time prior to the last date of submission of Tender, Tender Inviting Authority may, for any reason, whether on own initiative or in response to a clarification requested by a prospective Tenderer, may modify the condition in Tender documents by an amendment. All the prospective Tenderers who have purchased the tender document will be notified of the amendment in writing and that will be binding on them. In order to provide reasonable time to take the amendment into account in preparing their bid, Tender Inviting Authority may at discretion, extend the date and time for submission of tenders.

(b) Any person who has downloaded the tender document should watch for amendment, if any, on the website **janaushadhi.gov.in; pharmaceuticals.gov.in** and CPP portal i.e. **eprocure.gov.in** for which BPPI will not issue any separate communication to them.

(v) Interested eligible Tenderers may obtain further information in this regard from the office of the Tender Inviting Authority on all working days between 10:00 AM and 5:00 PM.

(vi) Certain products are reserved for purchase from Central Public Sector Undertakings (CPSU's). Orders for these items will be first placed with CPSU's.

4. TECHNICAL BID - COVER "A"

4.1. The Tenderer should furnish the following documents in a separate cover hereafter called **"Cover A". (All the documents submitted should be signed and sealed by the Tenderer in each page and photocopies of the documents should be attested by the Tenderer/authorised person).**

(a) Tender cost as indicated in 3(i) and Earnest Money Deposit as indicated in Clause 7 of the tender document shall be in the form of **Bankers Cheque or Demand Draft** favouring "Bureau of Pharma Public Sector Undertakings of India " , payable at Gurgaon/Delhi .Tender cost and EMD in any other form like ***cheque/cash/postal order*** etc. **will not be accepted.**

(b) Documentary evidence for the constitution of the Company/Firm such as Memorandum and Articles of Association, Partnership deed, Permanent Registration Number etc. with details of the Name, Address, Telephone Number, Fax Number, e-mail address of the firm and of the Managing Director / Partners / Proprietor. The list of present Directors in the Board of the Company duly certified by a Company Secretary of the Company/Practicing Company Secretary / Charted Accountant to be furnished.

(c) The Tenderer should furnish self attested photocopy of valid drug Manufacturing Licence for the product, duly approved by the Licensing Authority for each and every product quoted as per specification in the tender. The licence must have been duly renewed up to date and the items quoted shall be clearly highlighted in the licence. Original documents should be produced for verification when demanded. However, if renewal application for manufacturing licence has been filed, copy of same duly receipted by drug authorities must be enclosed along with the validity certificate from state licencing authority (SLA)

(d) Self attested photocopy of import license (in Form 10 with Form 41), as per Rule 122A of the Drugs and Cosmetics Act 1940, if the product is imported should be furnished. The licence must have been renewed up to date. A copy of a valid licence for the sale of Drugs imported by the firms issued by the State Licensing Authority shall be enclosed. Original documents should be produced for verification when demanded.

(e) The instruments such as power of attorney, resolution of board etc., authorizing an officer of the Tenderer should be enclosed with the tender duly signed by the Authorized signatory of the Company/Firm and such authorized officer of the Tenderer should sign the tender documents.

(f) Authorization letter nominating an officer of the Tenderer on the printed letter head of the company to transact the business with the BPPI to be furnished.

(g) MARKET STANDING CERTIFICATE (MSC) ISSUED BY THE STATE LICENSING AUTHORITY UNDER generic or brand name as a Manufacturer for each product quoted in the tender for a minimum 2 years (Certificate should be enclosed with list of items). In case of direct importer, evidence for importing the said items such as bill of landing, bill of entry and certificate of analysis are to be produced. MSC issued under brand name or under generic name (by the state licensing authority) will also be accepted but supplies will be accepted only in generic name.

(h) Non-conviction Certificate issued by the licensing authority of the State certifying that the firm/company has not been convicted. The certificate should not be more than 6 months old at the time of submission of technical bid.

(i) Valid Good Manufacturing Practices Certificate (GMP) as per Schedule-'M' (for manufacturers only)/WHO certificate issued by the Licensing Authority. The Tenderer shall also furnish a notarized declaration in the format given in **ANNEXURE-IV** declaring that the Tenderer complies with the requirements of GMP **(as per Schedule-'M')**. In case of Imported drugs, labels and product literature of all quoted product(s) must be submitted with WHO-GMP/certificate which is at par with WHO-GMP issued by exporting countries like U.S. FDA etc/COPP certificate of their Principal Manufacturing company/firm.

(j) Annual turnover statement for 3 years i.e. 2012-13, 2013-14 and 2014-15 should be furnished in the format given in **ANNEXURE-V** duly certified by the chartered Accountant. For 2014-15, if these documents are not audited, Provisional is required to be submitted.

(k) a. Latest Sales Tax Clearance certificate/returns are to be attached.
b. Latest Income tax assessment orders/returns filed are to be attached.

(l) (i) Undertaking (as in the proforma given in **ANNEXURE-VI**) for embossment of logos on strip of tablets, capsules, on labels of vials, Ampoules, bottles, tubes etc. as the case may be, and for supply of tablets/capsules in strips as per conditions specified under Clause 13..

(ii) Undertaking (as in the proforma given in **ANNEXURE-VI (A)**) for affixing the logo on the Secondary/Primary packing for the imported items along with Brand/Trade names.

(m) The details containing the name and address of the manufacturing premises / importing unit where the items quoted are actually manufactured should be given as per the format in **ANNEXURE-VII** along with exact address of registered/Corporate office.

(n) Documents, if any, to show that the manufacturing unit/importer has been recognized by any other Indian / International Standard Organizations etc. as applicable.

(o) The loan license bidder are required to submit all the documents as per tender requirements for own manufacturing unit plus 10 crores average annual turnover of host company/actual manufacturer.

(p) List of items quoted (The name & Drug code of the Items quoted should be Furnished and **the rate of those items should not be indicated in this list),** as shown in the **ANNEXURE-VIII** should be given in duplicate.

(q) A Checklist (**ANNEXURE- IX**) indicating the documents submitted with the tender document and their respective page number shall be enclosed with the tender document. The documents should be serially arranged as per this **ANNEXURE- IX** and should be securely tied or bound. If a company/firm has two or more separate manufacturing units at different sites / States, which are not separate entities then the company will be allowed to submit only one tender for all units but necessary document regarding separate manufacturing units will be submitted as a separate set with the same tender. However one bidder will be allowed to submit only one offer for one product.

(r) All the documents enclosed with the tender document should also be signed by the authorized official of the Tenderer.

4.2. The all documents indicated above should be kept and sealed in a separate Cover Superscribed as "TECHNICAL BID - COVER "A" – TENDER FOR THE SUPPLY OF DRUGS AND MEDICINES TO BUREAU OF PHARMA PSUs OF INDIA for the year 2015-2017 DUE ON **14/10/2015 at** 12:00 NOON. AND ADDRESSED TO THE TENDER INVITING AUTHOURITY, BUREAU OF PHARMA PSUs OF INDIA ,IDPL CORPORATE OFFICE COMPLEX, OLD – DELHI- GURGAON ROAD, DUNDAHERA, GURGAON- 122016 (HARYANA).

5. PRICE BID - COVER "B"

5.1. Cover "B" contains the Price Bid of the Tenderer.

(i) Bid should be computer printed. The correction should be avoided. However, in exigency, it shall be certified with full signature by the Tenderer, failing which the bid will be treated as ineligible. Corrections done with correction fluid will not be accepted.

(ii) Each page of the price bid should be duly signed by the Tenderer affixing the office seal.

(iii) (a) The Tenderer shall fill in manufacturing capacity, the landed price, total value, rate of CST against form C and Central excise duty applicable (yes/no) in respective column of **ANNEXURE-XVII** for the items quoted and also in excel sheets (supplied with tender

document) and such filled in **ANNEXURE-XVII in soft copy should be submitted in pen drive or compact disc (CD).**

(iv) **Determination of L1 bidder:** In determining the lowest evaluated price, the rate quoted per unit landed price as indicated in column No. 7 of the **ANNEXURE-XVII** shall be taken into consideration.

(v) The rate quoted in column 7 of **ANNEXURE -XVII** should be for a unit and for the given specification. **The rates quoted in paisa are to be in 2 digits.** The Tenderer is not permitted to change/alter specification or unit size given in the **ANNEXURE- X**

EXCISE DUTY-

(vi) The tenderers must indicate the rate of Excise duty applicable and payable by them irrespective of the fact whether the quoted prices are inclusive or exclusive of Excise Duty. If a tenderer states that the Excise duty is NIL/EXEMPTED, he must intimate the basis for the same and also confirm that no Excise Duty will be charged by him under any circumstances.

(vii) In case, no information about excise duty is given, it will be taken as inclusive.

ST/CST/VAT

(viii) The tenderers must indicate the rate of CST **against Form C** applicable.

(ix) In case supply is made from any place in Haryana, VAT shall be applicable.

5.2. The Tenderers shall submit duly signed **ANNEXURE-XVII in** a sealed cover Super scribed as **"PRICE BID COVER "B" –**

TENDER FOR THE SUPPLY OF DRUGS AND MEDICINES TO BPPI FOR THE YEAR 2015-2017".

The "Cover-B" should also be addressed to the **TENDER INVITING AUTHORITY, BUREAU OF PHARMA PSUs OF INDIA, IDPL CORPORATE OFFICE, IDPL COMPLEX, OLD- DELHI- GURGAON ROAD, DUNDAHERA, GURGAON-122016(HARYANA)**

5.3. Two sealed covers {Technical bid (Cover "A") {Refer Clause No.4.2} and Price Bid (Cover "B")} {Refer clause (5.2) } shall be placed in a separate cover which shall be sealed and Superscribed as

"TENDER FOR THE SUPPLY OF DRUGS AND MEDICINES TO "BPPI" FOR THE YEAR 2015-2017 DUE ON 13/10/2015 AT 12.00 NOON and addressed to the

TENDER INVITING AUHORITY, BUREAU OF PSUs OF INDIA, IDPL CORPORATE OFFICE, IDPL COMPLEX, OLD- DELHI- GURGAON ROAD,

DUNDAHERA, GURGAON-122016(HARYANA), which shall be submitted within the date and time as specified in Clause 1(a).

5.4. If the last date for submission of Tender is declared holiday, the tenders may be submitted on the next working day upto 12.00 A.M.

6. OPENING OF COVER "A" AND COVER "B" OF TENDER

6.1 Only authorized official as indicated in Clause 4.1. (f) are entitled to be present at the time of opening of Technical Bid - Cover "A" of the tender submitted by them.

6.2 Tenderers, who are found eligible on satisfying the criteria for technical evaluation and inspection, will only be invited to be present at the time of opening of Price Bid - Cover "B" of the tender.

7. EARNEST MONEY DEPOSIT

7.1. The Earnest Money Deposit referred to under Clause 3(iv) & 4.1(a), shall be **Rs. 1 lakh. The Earnest Money Deposit shall be paid in the form of Bankers Cheque or Demand Draft in favor of BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA, payable at Gurgaon/Delhi.(ANNEXURE-X).**

7.2.(i) The tender submitted without sufficient EMD will be summarily rejected.

(ii) The Earnest Money Deposit will be refunded to the successful bidders within 30 days from the date of signing the contract agreement and on the deposit of Security Deposit.

(iii) The Earnest Money Deposit (EMD) of the unsuccessful bidders will be returned after finalization of tender/signing of agreement with eligible bibber.

(iv) The Earnest Money Deposit (EMD) will be forfeited, if the tenderer withdraws his bid any time after opening of price bid / non execution of agreement /undertaking within the period prescribed.

(v) The Earnest Money Deposit (EMD) will be forfeited, in case of the lowest bidder, fails to execute the contract agreement and / or deposit the security Deposit within the stipulated time (**ANNEXURE-XI).**

(vi) Tenderer may be exempted from the payment of EMD, provided that valid **registration** certificate from NSIC duly self-attested is produced **for the product for which bidder has submitted quotation.**.

(vii) PSUs are exempted from the payment of EMD.

8. OTHER CONDITIONS

8.1.(i) The details of the required drugs, medicines, etc., are shown in **ANNEXURE - XII**. ***The tender quantity mentioned herein is not a fixed procurement quantity and it is only a tentative requirement and may be increased or decreased*** by the BPPI, at its discretion, depending on it is actual need. Though the tentative quantity is indicated in the agreement, the BPPI, will confirm the actual requirement then / there through purchase order/orders. The tenderers shall supply the drugs only on the basis of the purchase order issued time to time within validity of contract period by the BPPI. Any supply without a valid purchase order will not be acceptable by BPPI and the BPPI shall not be responsible for any loss on this account.

(ii) However, once the purchase order/orders is/are issued by the BPPI, the tenderer shall not renege from the commitment of supplying the quantity mentioned in the agreement / undertaking.

(iii) The rates quoted shall not be varied with the ordered quantity during the full contract period.

8.2. Tender has been called for in the **Generic name of drugs**. The Tenderers should quote the rates for the generic products only. The composition, strength and packing of each product should be as per specifications given in **ANNEXURE -XII**. Any variation, if found, will result in rejection of the tender. However the imported/combination drugs are allowed to quote in trade / brand name.

8.3. Rates (inclusive of Customs duty, packing & forwarding charges, transportation, insurance and any incidental charges, but exclusive **CST against form C**/VAT (Sales Tax) and excise duty) should be quoted for each of the required drugs, of medicines etc., separately on door delivery basis according to the unit ordered. Tender for the supply of drugs, medicines, etc. with cross conditions like "AT CURRENT MARKET RATES" shall not be

accepted. Handling, clearing, transport charges etc., will not be paid separately. The delivery should be made as stipulated in the purchase order placed with Tenderers.

8.4. Each bid must contain not only the unit rate but also the total value of each item quoted for supply in the respective columns. The aggregate value of all the items quoted in the tender shall also be furnished.

8.5. The price quoted by the tenderers shall not, in any case exceed the DPCO controlled price, if any, fixed by the Central/State Government, the Maximum Retail Price (MRP) and the selling price of the tenderer. Tender Inviting Authority at its discretion, may exercise, the right to revise the price at any stage so as to conform to the controlled price or MRP or the selling price of the tenderer as the case may be. This discretion will be exercised without prejudice to any other action that may be taken against the Tenderer.

8.6. The rates quoted and accepted will be binding on the Tenderer for the full contract period of two years and any increase in the price will not be entertained till the completion of this contract period. Accordingly this clause will be applicable for all orders placed during the contract period.

8.7. No Tenderer shall be allowed at any time and on any ground, whatsoever it may be, to claim revision or modification in the rates quoted by them. Representation to make correction in the tender documents on the ground of Clerical error, typographical error, etc., committed by the Tenderers in the Bids shall not be entertained after submission of the tenders. Cross Conditions such as "SUBJECT TO AVAILABILITY", "SUPPLIES WILL BE MADE AS AND WHEN SUPPLIES ARE RECEIVED" etc., will not be entertained under any circumstances and the tenders of those who have mentioned such conditions shall be treated as incomplete and accordingly the Tender will be summarily rejected.

8.8. Supplies should be made directly by the tenderer and not through any other Agency / Dealer / Distributors.

8.9. The Tenderer shall allow inspection of the factory at any time after the opening of technical bid and during the entire contract period by a team of Experts/Officials nominated by the Tender Inviting Authority for the purpose. The Tenderer shall extend necessary cooperation to such team in inspection of the manufacturing process, quality control measures adopted etc., in the manufacture of the items quoted. If Company/Firm does not allow for any such inspection, their tenders will be rejected. If any such situation arises after placement of contract, the same shall be cancelled at the firm's risk cost.

8.10 "MRP inclusive of all taxes" is to be printed on each unit/label. MRP will be intimated to successful bidders at the time of placing purchase orders.

9. ACCEPTANCE OF TENDER

9.1. Evaluation of the tender and determination of the L1 rate (Lowest rate) will be done on the basis of rate per unit landed price as mentioned in column 7 of **ANNEXURE-XVII.** Negotiation if required will be done at our premises and the same will be done strictly as per Central Vigilance Commission guidelines.

9.2. BPPI reserves the right to accept or reject the tender for the supply of all or any one or more items of the drugs tendered for in a tender without assigning any reason.

9.3. BPPI or its authorized representative(s) has/have the right to inspect the manufacturing premises of Tenderers, before accepting the rate quoted by them or before releasing any purchase order(s) or at any point of time during the continuance of tender and also has the right to reject the tender or terminate/cancel the purchase orders issued and/or not to place further order, based on adverse reports brought out during such inspections.

9.4. The acceptance of the tenders will be communicated to the lowest Tenderers in writing.

10. SECURITY DEPOSIT AND AGREEMENT

10.1Security Deposit:

On being informed about the acceptance of the tender and at the time of signing the Agreement, the Tenderer shall pay the Security Deposit @ 5% of the value of order in the form of ***Demand Draft or irrevocable Bank Guarantee*** in favour of Bureau of Pharma Public Sector Undertakings of India from any scheduled Bank. In case the Security Deposit is paid in form of Bank Guarantee, the bank guarantee shall be valid for a period beyond 3 months of the validity of the contract. The format of Bank Guarantee is at **ANNEXURE-XIII.**

10.2. The Tenderer shall execute an agreement on a non- judicial stamp paper of value of Rs.100/- (stamp duty to be paid by the Tenderer) within 15 days from the date of the intimation from BPPI informing that his tender has been accepted. The Specimen form of agreement is available in **ANNEXURE-XIV.**

10.3. The Tenderer shall not, at any time, assign, sub-let or make over the contract or the benefit thereof or any part thereof to any person or persons what so ever.

10.4. All notices or communications relating to and arising out of this agreement or any of the terms thereof shall be considered duly served on or given to the Tenderer if delivered to him or left at the premises, places of business or abode as provided by the tenderer.

10.5. If the lowest Tenderer fails to execute the agreement and/or to deposit the required security deposit within the time specified or withdraws the tender, after the intimation of the

acceptance of the tender or owing to any other reasons to undertake the contract, the contract will be cancelled and the Earnest Money Deposit deposited by the tenderer along with the tender shall stand forfeited by the BPPI and the firm will also be liable for all damages sustained by the BPPI apart from blacklisting and other penal actions.

10.6. The security deposit of supplier will be returned by BPPI only after the supplier has given undertaking to replace such medicines and indemnify BPPI against any loses on account of quality parameters.

11. METHODOLOGY FOR PLACING ORDERS

For the above purpose the following procedures will be adopted

(a) After the conclusion of Price Bid opening (Cover B), the rates offered by tenderers for each product are evaluated and lowest acceptable rate (L1 Rate) arrived at is declared and that tenderer is informed.

(b) The Successful Tenderer is eligible for the placement of Purchase Orders only after depositing the required amount as Performance Security and on execution of the agreement.

(c) If two or more than two Tenderer's are declared as lowest suppliers for the same item(s), such Tenderers shall execute necessary agreement as specified in the Tender Document on depositing the required amount as Performance Security and on execution of the agreement such Tenderer's are eligible for the placement of Purchase Orders for such item(s) for which they are declared as lowest. Placement of order shall be shared equally amongst these bidders subject to their manufacturing capacity.

(d) In the case of purchase of goods where the quantity offered at the lowest price is less than the total quantity required, the BPPI may, after placing orders with the lowest evaluated Tenderer for the entire quantity offered by such Tenderer subject to his ability to supply, require all the other eligible Tenderers who participated in the tender and offered a price higher than that offered by the lowest evaluated Tenderer, to submit sealed offers of the quantity they would be willing to supply at the price quoted by the lowest evaluated Tenderer, and thereafter place orders for the remaining required quantity with all those who match the lowest evaluated price such that those who bid lower prices in the original tender get a higher priority for supply.

(e) If a supplier fails to execute 3 successive supply orders successfully, their security deposit shall be FORFEITED and their bad performance shall be kept in record of BPPI for future dealing as considered appropriate by BPPI with stipulated delivery period including L.D. Period.

(f) Notwithstanding anything contained in para (e) above, the supplier, after committing the default in supply either partly or fully, can inform the BPPI about his willingness to execute the Purchase Order during the tender period. The BPPI at discretion may consider the willingness of the supplier on merit. However, such supplies will be subjected to the levy of Liquidated Damages, unexecuted fine and other penalties as stipulated in the tender document, agreement and purchase order.

(g) The supplier shall start supply of the Drugs/Medicines required by BPPI at Central Ware House (CWH), Gurgaon within the stipulated period.

(h) The Drugs/Medicines supplied in excess of the ordered quantity shall not be accepted and the supplier shall take back the excess at their cost. BPPI will not be responsible for the loss to the supplier and will not entertain any demand/claim.

(i) The supplier shall supply the Drugs/Medicines at the CWH, Gurgaon along with copy of Purchase order, copy of test reports and 3 original copies of Invoice. No payment will be processed without test reports.

(j) The supplier shall take utmost care in supplying the quality Drugs/Medicines and ensure that the batch number mentioned in the packages of the Drugs/Medicines tally with the batch number mentioned in the Invoice produced to BPPI for payment. Also the supplier shall ensure the quantity relevant to the Batch Number of the Drugs/Medicines is mentioned in the invoice.

(k) It is the duty of the supplier to supply Drugs/Medicines at the CWH Gurgaon and supply shall conform to the conditions mentioned in the provisions of tender documents, viz., logo, nomenclature, specification etc.,

(l) Subject to above, BPPI will process the invoices submitted by the supplier and the payments against supply will be made within 30 days from the date the Drugs/Medicines supplied has been declared of STANDARD QUALITY, by the Empanelled laboratory of BPPI subject to various terms and conditions of the tender.

(m) Subject to the conditions mentioned in the Purchase Order, Tender Document, Agreement executed by the supplier and here under, the Supplier is entitled for the payment against supply. In case of any discrepancy in levy of LD, Penalty, Unexecuted Fine, Short Passing of Bills, such discrepancy shall be intimated within 30 days from the date of receipt of payment, failing which BPPI will not entertain any claim thereafter.

(n) BPPI reserves the right to place upto 50% additional purchase order of the quantities as contracted within validity of contract.

12. SUPPLY CONDITIONS

12.1. Purchase orders will be issued to the Tenderer(s) at the discretion of the BPPI as per actual requirements. All the supplies shall be received at the central warehouse at Gurgaon.

12.2. Within 3 days from the receipt of purchase orders the Tenderer should inform BPPI through fax and mail the confirmation for the receipt of the purchase order.

12.3. The Tenderer should also fax and mail the details of supply dates as specified in Annexure, to BPPI within 7 days from the receipt of the purchase order.

12.4. (a) For the first purchase order, the supplier must supply the ordered quantity CWH Gurgaon within 60 days from the date of Purchase Order.

(b) For Subsequent purchase orders, the supplier shall complete the supply within 45 days from the date of purchase order at the destinations mentioned in the purchase order.

(c) If the above day for 12.4 (a) & (b) above happened to be a holiday for BPPI, the supply should be completed by 5.00 PM on the next working day.

(d) In case of Non- execution of the order, BPPI reserves the right to place purchase orders (partially/fully) on alternate source at the risk and cost of the default tenderer(s) without any notice/Information.

(e) If the Tenderer fails to execute the supply within the stipulated time, the BPPI is at liberty to make alternative arrangement for purchase of the items for which the Purchase orders have been placed, from any other sources or in the open market or from any other Tenderer who might have quoted higher rates, at the risk and the cost of the defaulted supplier and in such cases the BPPI has every right to recover the cost and impose Liquidated Damages as mentioned in Clause 18.

(f) The supplier may continue the supply of unexecuted quantity after 60th day in case of 12.4(a) above and after 45th day in case of 12.4(b) above, however Liquidated Damages as specified in clause 18.1 and 18.2 of the tender conditions will be levied on the quantity supplied after the 60th day and 45th day respectively. However, no supplies will be accepted after 120 days from the date of issue of purchase order and the purchase order shall be cancelled at the risk and cost of the supplier.

12.5. Supplier shall complete the earliest pending purchase order before commencing the supply of subsequent purchase orders.

12.6. The supplied medicines and Drugs (covered in SCHEDULE "P" of Drugs and Cosmetics Act) should have the prescribed potency throughout the shelf life period as prescribed in the Drugs and Cosmetics Act 1940 and rules there under and in relevant Pharmacopoeias.

12.7. The Tenderer must submit an Analysis report for every batch of drug along with invoice. In case of failure on part of the supplier to furnish such report, the batch of drugs will be returned back to the suppliers and he is bound to replenish the same with Govt. approved lab test report. The Drugs and medicines supplied by the successful Tenderer shall be of the best quality and shall comply with the specifications, stipulations and conditions specified in the tender.

12.8. Tenderer should supply the product, within 2 months from the date of manufacture of that product. Products beyond 2 months from the date of manufacture shall not be accepted. For example product having manufacturing of April 2015 must be supplied before June 30, 2015.For sterile products having shelf life of 18 months or more, products within 90 days (3 months) from date of manufacture will be accepted.

For imported products, 75% of shelf life should be available at time of supply.

12.9. The order stands cancelled at the end of 120th day from issue of Ist Purchase order/ from issue of the subsequent purchase order after levying penalty on the value of unexecuted order as specified under Clause 18.3. Further, the Tenderer shall also be liable to pay other penalties as specified under Clauses 18. Security Deposit of such suppliers against the contract/agreement shall also be forfeited. Their tender/offer against future tender of BPPI shall not be considered keeping in view of bad performance in previous contract/agreement.

12.10. If at any time the Tenderer has, in the opinion of the BPPI delayed the supply of drugs due to one or more reasons related to Force Majeure events such as riots, mutinies, wars, fire, storm, tempest or other exceptional events at the manufacturing premises, the time for supplying the drugs may be extended by the BPPI at discretion for such period as may be considered reasonable. However such extension shall be considered only if a specific written request is made by the Tenderer within 10 days from the date of occurrence of such event with necessary documentary evidence. The exceptional events does not include the Scarcity of raw material, Increase in the cost of raw material, Electricity failure, Labour disputes/Strikes, Insolvency, and Closure of the Factory/Manufacturing unit on any grounds etc.

12.11. The supplier shall not be liable to pay LD and forfeiture of security deposit for the delay in executing the contract on account of the extension of supply period on the ground of force majeure events.

13. LOGOGRAMS

Logogram means, wherever the context occurs, the design as specified in **ANNEXURE-VI. The name of the drug shall be mentioned in English and Hindi.**

13.1. Tenders for the supply for Drugs and medicines etc., shall be considered only if the Tenderer gives an undertaking that the product(s) will be prepared as per the specifications such as strength, minimum size and packed with appropriate size of the strips/blisters/bottles/tubes etc as per the design enclosed as per **ANNEXURE –VI** &**VI -A**.

13.2. All tablets and capsules have to be supplied in packing as specified in product list (**ANNEXURE XII**) and shall also conform to Schedule P1 of the Drugs & Cosmetics Act & Rules 1945, wherever it applies. Affixing of stickers and rubber stamps shall not be accepted and supplies will be returned back at supplier's cost.

13.3. Vials, Ampoules (more or equal than 5 ml) and Bottles containing the items tendered for should also carry the printed Jan Aushadhi logogram of proportionate size.

13.4. Failure to supply Drugs etc., with the printed logogram of proportionate size will be treated as breach of the terms of agreement / violation of tender conditions. The purchase order shall be cancelled at the risk and cost of the supplier. However if such failure continuous despite notice, will be viewed as a serious lapse and initiate blacklisting of the supplier.

Tenderers who are not willing to agree to conditions above will be summarily rejected.

14. PACKING

14.1. The drugs and medicines shall be supplied in the package specified in **ANNEXURE -XII** and **ANNEXURE -XV** and the package shall carry the logograms of proportionate size specified in **ANNEXURE –VI, VI -A**. Non affixing of logograms will be treated as violation of tender conditions and fine will be deducted from the amount payable as per condition in Clause 18.5

14.2. The minimum size of each tablet should be 6.4 mm in diameter and the minimum size of the blister packing and strip packing should be 70mm x 30 mm and 50mm x 130mm respectively. Failure to comply with this shall lead to non-acceptance of the goods besides imposition of penalties as per clause 18.5.

14.3. The packing in each carton shall be strictly as per the specification mentioned in **Annexure-XV**. The outer carton should be of white board with a minimum of 300 GSM with **Gloss laminated/UV varnished** packing for the strips, blisters, ointments, creams etc. and for ampoules and vials should be with white board of 350 GSM**.** Failure to comply with this shall lead to non-acceptance of the goods besides imposition of penalties as per clause 18.5. Storage conditions must be indicated on outer label.

14.4. The cap of bottle preparations should not carry the name of the supplier.

14.5. The labels in the case of Injectable preparations should clearly indicate whether the preparations are meant for Intravenous (IV), Intra Muscular (IM), Intra Dermal (ID), Subcutaneous (SC) administration etc.

14.6. It should be ensured that only first-hand virgin packaging material of uniform size, including bottle and vial, is used for packing.

14.7. All primary packing containers should be strictly conforming to the specification included in the relevant pharmacopoeia.

14.8. Packing should be able to prevent damage or deterioration during transit.

14.9. In the event of items of drugs supplied found to be **not as per specifications in respect of their packing and logogram**, the BPPI is at liberty to make alternative purchase of the items of drugs and medicines for which the Purchase orders have been placed from any other sources or in the open market or from any other Tenderer who might have quoted higher rates, at the risk and the cost of the supplier. In such cases the BPPI has every right to recover the cost and impose penalty as mentioned in Clause 18 & 19.

14.10. Designs of packaging with the logograms shall be subject to approval by BPPI within 7 days of receipt of the same from the supplier, as per the specifications. In case of failure of BPPI to do so, the supplier may go ahead with the design as per the specification in **ANNEXURE XII and XV.**

15. QUALITY TESTING

15.1. Samples of supplies from each batch will be chosen at the point of despatch or receipt of supply or distribution/storage points for testing at discretion of BPPI. The samples will be sent to different laboratories including Government Drugs Testing Laboratory for testing as

decided by the BPPI Handling and testing charges will be deducted by BPPI for the above purpose, as specified in Clause 17.

15.2. The Drugs shall have the active ingredients at the prescribed level as indicated in official compendiums throughout the shelf life period of the drug. The samples will be drawn periodically throughout the shelf life period and if found "Not of Standard Quality", the cost of entire batch paid will be recovered whether consumed fully/partially. Also action will be initiated for blacklisting as per clause No.19 irrespective of the period of supply. The supplies will be deemed to be completed only upon receipt of the quality certificates from the laboratories. Samples which do not meet quality requirement shall render the relevant batches liable to be rejected. If the sample is declared to be "Not of Standard Quality" or spurious or adulterated or misbranded, such batch/batches will be deemed to be rejected goods.

15.3. In the event of the samples of Drugs and medicines supplied fails in quality tests or found to be not as per specifications, the BPPI is at liberty to make alternative purchase of the items of drugs and medicines for which the Purchase orders have been placed from any other sources or in the open market or from any other Tenderer who might have quoted higher rates, at the risk and the cost of the supplier and in such cases the BPPI has every right to recover the cost and impose penalty as mentioned in Clause 19.

15.4. The supplier shall furnish evidence of the basis for shelf life and other stability data concerning the commercial final package on request by the BPPI. In case of any complaint in the field, the B.M.R/B.P.R for the particular batch of the product(s) supplied shall be produced when demanded.

15.5. The products should conform to the standards of IP/BP/USP/EP/JP as the case may be. In case the product is not included in the any of the said compendiums, the supplier, upon award of the contract, must provide the reference standards and testing protocols for quality control testing. For imported drugs, respective Country's Pharmacopeial standards shall be acceptable (even if the product is official in IP).

15.6. The case of admixture of drugs will be treated as a violation of tender conditions and fine will be levied as per clause 19. If such lapses happens more than twice in a tender period such cases will be treated as "Misbranded Drugs".

16. PAYMENT PROVISIONS

16.1. No advance payments towards costs of drugs, medicines etc., will be made to the Tenderer.

16.2. Payments towards the supply of drugs and medicines will be made within 60 days from the date of receipt of goods, strictly as per the tender terms and condition. The payment will be made either by means of a/c payee Cheque or through RTGS (Real Time Gross

Settlement System)/Core Banking/NEFT. The Tenderer shall furnish the relevant details in original **(ANNEXURE -XVI)** to make the payment through RTGS/Core Banking/NEFT.

16.3. All bills/Invoices should be raised in triplicate and in the case of excisable Drugs and Medicines, the bills should be drawn as per Central Excise Rules in the name of Bureau of Pharma Public Sector Undertakings of India. IDPL Complex, Dundahera, Gurgaon 122016 or in the name of any other authority as may be designated.

16.4. (i) Payments for supply will be considered only after supply of minimum 50% of Drugs ordered in the individual Purchase Order PROVIDED reports of Standard Quality on samples testing are received from Government Analyst or Approved Laboratories of BPPI

(ii) However, in case of cancellation of a particular purchase order due to failure in delivery, payment for part supplies less than 50% of the purchase order quantity on the date of cancellation of the purchase order may be considered for release of payment subject to the following:

(a) If the Tenderer have supplied at least 50% of the quantity ordered in the subsequent purchase order within 60 days from the issue of such purchase order.

(b) If further purchase order is not placed with the supplier due to any reason, not attributable to the supplier, the amount eligible will be paid within 60 days from the date of last supply.

(c) The payment for part supply as mentioned above will subject to the deduction of liquidated damages, penalty towards unexecuted quantity, risk and cost etc., as per the tender conditions.

16.5. If at any time during the period of contract, the price of tendered items is reduced or brought down by any law or Act of the Central or State Government or by the Tenderer himself, the Tenderer shall be bound to inform the BPPI immediately about such reduction in the contracted prices. Tender Inviting Authority is empowered to unilaterally effect such reduction as is necessary in rates in case the Tenderer fails to notify or fails to agree for such reduction of rates.

16.6.(a) In case of any increase of decrease in the taxes, such as excise duty, customs duty, sales tax, VAT etc., after the date of submission of tenders and during the tender period, such variation in the taxes will be to the account of the BPPI. For claiming the additional cost on account of the increase in taxes, the Tenderer should produce the proof of having paid additional amount on this account on the goods supplied to BPPI from the concerned Excise authorities and also must claim the same in the invoice separately. However the basic price structure and the price of the Drugs approved under the tender shall not be altered.

Similarly if there is any reduction in the taxes and statutory levies as notified by the Govt., after the date of submission of tender, the Tenderer will be paid based on the unit rate worked out on the basis of the reduced taxes/statutory levies without any change in the basic price or the price structure of the drugs approved under the tender.

Any increase or decrease in taxes and statutory levies will be considered based on the notification issued by the Government.

However, if the firm supplies after originally stipulated Delivery period, increase in Excise duty/taxes due to statutory variation in Excise duty/taxes shall be borne by the supplier. In case of decrease in Excise duty/taxes due to statutory variation in Excise duty/taxes, the same shall be passed on by the supplier to the BPPI.

(b) In case of successful bidder enjoying excise duty exemption on any criteria of turnover, area based etc., such bidder will not be allowed to claim excise duty at a later point of time, during the tenure of contract, when the excise duty is chargeable on goods manufactured.

16.7. Form 'C' shall be provided by BPPI, wherever required. The tenderers should quote the concessional rate of CST applicable in their bids.

17. HANDLING & TESTING CHARGES:

In all supplies, 1.5% of the supply value shall be deducted towards handling & testing charges.

18. LIQUIDATED DAMAGES AND OTHER PENALTIES:

18.1. If the supply reaches the designated places or Central Warehouse after 5 PM of 60th day from the date of issue of the Ist purchase order and after 5 PM of the 45th day from the date of issue of the subsequent purchase order, a liquidated damages will be levied at 2% per week or part thereof, subject to maximum of 10% irrespective of the fact that whether the BPPI has suffered any damage/loss or not, on account of delay in effecting supply. If the $60^{th}/45^{th}$ day happens to be a holiday the supply will be accepted on the next working day without any penalty.

18.2. If the supply is received in damaged condition, open delivery of the supplies shall be received, wherein it is possible to physically inspect the shipment. Damaged products shall not be accepted.

18.3. All the Tenderers are required to supply the product(s) with printed logogram of appropriate size on the strips, blisters, vials, ampoules & bottles and with prescribed packing

specification. If there are any deviation in these Tender conditions, action will be taken to blacklist the product and/or a separate damages will be levied @ 5% of value of the defaulted quantity irrespective of the Tender Inviting Authority having actually suffered any damage/loss or not, without prejudice the rights of alternative purchase specified in Clause No.14.11 and 13.4.

19. DEDUCTION & OTHER PENALTIES ON ACCOUNT OF QUALITY FAILURE:

19.1. If the samples do not conform to statutory standards, the Tenderer will be liable for relevant action under the existing laws and the entire stock in such batch has to be taken back by the Tenderer within a period of 30 days of the receipt of the letter from the BPPI Such stock shall be taken back at the expense of the Tenderer. The BPPI has the right to destroy such "NOT OF STANDARD QUALITY DRUGS" if the Tenderer does not take back the goods within the stipulated time. The BPPI will arrange to destroy the "NOT OF STANDARD QUALITY DRUGS" after the expiry of 30 days mentioned above without further notice, and shall also collect demurrage charges calculated at the rate of 2% per week on the value of the drugs rejected till such time stipulated.

19.2. If any items of Drugs/Medicines supplied by the Tenderer have been partially or wholly used or consumed after supply and are subsequently found to be in bad odour, unsound, inferior in quality or description or otherwise faulty or unfit for consumption, then the contract price or prices of total such batches supplied will be recovered from the Tenderer, if payment had already been made to him. In other words the Tenderer will not be entitled to any payment whatsoever for Items of drugs found to be of "NOT OF STANDARD QUALITY" whether consumed or not consumed and the Tender Inviting Authority is entitled to deduct the cost of such batch of drugs from any amount payable to the Tenderer. On the basis of the nature of failure, action will be initiated to blacklist the product/supplier.

19.3. For the supply of Adulterated/Spurious/Misbranded drugs, as defined in the Drugs and Cosmetics Act, 1940, to BPPI, BPPI reserves the right to blacklist the supplier.No further supplies shall be accepted from the firm/company. If the tenderer is blacklisted, the tenderer shall also not be eligible to participate in tenders of Tender Inviting Authority of BPPI for supply of Drugs and Medicines for a period of 5 years from the date of blacklisting. In case of supply of NOT OF STANDARD QUALITY drug(s) to BPPI, the product shall be blacklisted by BPPI and no further supplies shall be accepted for the particular drug(s). The Tenderer shall also not be eligible to participate in tenders of BPPI for supply of such Drugs and Medicines for a period of 2 years from the date of blacklisting. In addition, the Director of Drugs Control of concerned State will be informed for initiating necessary action on the Tenderer in their state. Security deposit will also be forfeited without any intimation.

19.4. The Tenderer shall furnish the source of procurement of raw material utilized in the formulations, if required by the BPPI. The BPPI reserves the right to cancel the purchase orders, if the source of supply is not furnished.

19.5. The decision of the BPPI or any officer authorized by him, as to the quality of the supplied drugs, medicines etc., shall be final and binding. In such cases, the BPPI will be at liberty to terminate, the contract either wholly or in part on 30 days notice. The Tenderer will not be entitled for any compensation whatsoever in respect of such termination besides forfeiture of Security deposit.

19.6. For contravention of the stipulations of the contract or for other justifiable reasons, the contract may be terminated by the BPPI, and the Tenderer shall be liable to pay for all losses sustained by the BPPI in consequence of the termination which may be recovered from the Tenderer, as per rules besides forfeiture of Security deposit.

19.7. Non performance of any of the contract conditions and provisions will disqualify a firm from participating in the tender for the next 2 years besides forfeiture of Security deposit.

19.8. In the event of making Alternative Purchase, as specified in Clause 12.4 (a), Clause 14.11 and in Clause 15.3 penalty will be imposed on the supplier. The excess expenditure over and above contracted prices incurred by the BPPI in making such purchases from any other sources or in the open market or from any other Tenderer who has quoted higher rates and other losses sustained in the process, shall be recovered from the Security Deposit or from any other money due and become due to the supplier and in the event of such amount being insufficient, the balance will be recovered personally from the supplier as per rules.

19.9. In all the above conditions, the decision of the BPPI shall be final and binding.

20. BLACK LISTING IN THE EVENT OF WITHDRAWL FROM THE TENDER, AND NON-ADHERENCE TO THE QUALITY STANDARDS AND SUPPLY SCHEDULE

20.1. BLACKLISTING OF PRODUCT/TENDERER ON WITHDRAWAL OF TENDER

(a) If the Tenderer(s) fails to execute the agreement / to perform the obligations under the tender conditions / commits default in the performance of the contract, such Tenderers will be blacklisted for a period of 2 years by BPPI from the date of observing the defect besides forfeiture of Security deposit.

BLACKLISTING FOR QUALITY FAILURE

20.2.1. Quality Test by the Empanelled Laboratories of BPPI

a. Each and every batch of drugs/medicines shall be subjected to quality test by the Empanelled laboratories.

b. The samples collected from each batch of supply of the each drugs will be sent to the empanelled testing laboratories for testing the quality of drugs. In addition to the above BPPI shall also draw the samples of products supplied in the market place and get the same tested, to make sure the products are conforming to quality requirements.

c. If such sample passes quality test in all respects, BPPI will instruct its Warehouse to release such items of drugs.

d. If the sample fails in quality test and report is received certifying that sample is "NOT OF STANDARD QUALITY", one more sample shall be drawn from the same batch and to be sent to Government Laboratory for quality testing.

(i) If such sample passes the quality test as per the report of Government Laboratory, the drugs representing the sample shall be qualified for issue to various Institutions.

(ii) If such sample fails in the quality test, as per the report of the Government Laboratory, the drugs of the batch are not qualified for issue and the supplier shall take back the drugs supplied in that batch, besides taking other actions as per the Tender conditions by BPPI.

(iii) If such Sample fails in quality test for ASSAY content of less than 50% as per the Government Analyst report, such product of the tenderer will be blacklisted for two years.

(iv) If **3** batches of a particular item supplied by the supplier is reported to be failing in ASSAY content (above 50% but below prescribed limit) and/or other parameters, then the particular item of the firm shall be blacklisted after observing procedure laid down in Para 20.2.4 besides forfeiture of Security Deposit of that particular product(s).

f. In all the cases the reports received from the Government Drug Testing Laboratory will be conclusive and final and binding on the suppliers.

20.2.2 Quality Test by Statutory Authorities:

(a) On complaint from Drug Inspector(s) during their Test of statuary sample, that the particular drug has been reported to be of "NOT OF STANDARD QUALITY", the issue of available stock of the particular item will be stopped. Further, the available stock of the product in hospitals will be retrieved. If the sample is reported to have less than 50% of content, the particular product will be **blacklisted for 2 years from the date of intimation of blacklisting.**

(b) If 4 batches of a particular item supplied by the supplier is reported to be failing in **ASSAY content (above 50% but below prescribed limit) and/or other parameters,**

then the particular item of the firm shall be blacklisted for a period of **2 years** from the date of intimation after observing procedure laid down in Para 20.2.4.

(c) If a single batch of any product(s) supplied by the company/firm declared as Adulterated/spurious/ Misbranded, as defined in the Drugs and Cosmetics Act, 1940, by the Government Authorities during the relevant tender period, the company/firm shall be blacklisted for a period of **5 years from the date of blacklisting** after observing procedure laid down in Para 20.2.4.

20.2.3 BLACKLISTING OF THE SUPPLIER FOR QUALITY FAILURE:

a. In case of any sample declared as Adulterated/spurious/ Misbranded, as defined in the Drugs and Cosmetics Act, 1940, by the Government Authorities during, the company/firm shall be blacklisted for a period of **5 years** from the date of intimation besides forfeiture of security deposit in full after observing the procedure laid down in Para 20.2.4.

20.2.4 Procedure for Blacklisting:

(i) On receipt of complaint from Distributer/retailers/customers or report from Govt. Analyst/Drug Testing Laboratory indicating that a particular Item/Drug is "**NOT OF STANDARD QUALITY/ ADULTERATED/ SPURIOUS/ MIS-BRANDED" (**As the case may be), a show cause notice shall be issued to the supplier calling for explanation within 7 days from the date of notice. On receipt of explanation from the supplier, the CEO, BPPI may take appropriate action on merits of the case and impose penalty including the blacklisting of the particular item of the product/company or firm as deemed fit besides forfeiture of Security deposit

(ii) If a particular item of the drug has been blacklisted according to the procedure stated above, the supplier is not eligible to participate in any of the tenders for that particular item floated by the BPPI until the period of blacklisting is over.

(iii) If a supplier company/firm is blacklisted according to the procedure stated above, such supplier is not eligible to participate in any of the tenders floated by the BPPI until the period of blacklisting is over.

20.3 BLACKLISTING FOR NON-SUPPLY:

Notwithstanding various actions and penalties for non-supply and/or delayed supply of the drugs and medicines as stipulated in the terms and conditions of the tender, the BPPI shall take action against the supplier as follows:

(a) If the supplier fails to execute at least 50% of the ordered quantity as mentioned in a single Purchase order and such part supply for **any three Purchase orders of the same**

drug, then the product of the supplier will be blacklisted and becomes ineligible to participate in any of the tenders for that particular item(s) by BPPI for a period of **2 years** from the date of intimation for blacklisting besides forfeiture of security deposit of that product(s)

(b) If the supplier supplies more than one item and 50% of such items are blacklisted, the firm is liable to be blacklisted for a period of **2 years from the date of intimation** besides forfeiture of security deposit in full

20.4. Purchase orders, if any, already issued before taking any blacklisting action or orders given in past will not be affected in view of action taken as per above guidelines but all strict quality checks shall be observed for each supply of products.

20.5. The blacklisting of particular product or company/firm will be done without prejudice to other penalties which may be imposed as per the conditions of Tender documents and also to other actions which may be initiated under Drugs and Cosmetics Act 1940 or any other law of Land. BPPI will display names of such blacklisted product(s) and company/firm on its website and also circulate the same among other state Government / Central Government and its Drug procurement agencies including respective State Drugs Control Department where the company or firm is located.

21. SAVING CLAUSE

No suit, prosecution or any legal proceedings shall lie against the Tender Inviting Authority or any person for anything that is done in good faith or intended to be done in pursuance of the tender.

22. RESOLUTION OF DISPUTES

(i) The BPPI and the supplier shall make every effort to resolve, amicably by direct informal negotiation any disagreement or dispute arising between them under or in connection with the contract,

ARBITRATION AND JURISDICTION

Normally, there should not be any scope of dispute between the BPPI and the supplier after entering into a mutually agreed valid contract/agreement.

However, due to various unforeseen reasons, problems may arise during the progress of the contract/agreement leading to disagreement BPPI and the supplier shall first try to resolve the same amicably by mutual Consultation. If the parties fail to resolve the dispute by such mutual consultation within twenty-one days, then, depending on the position of the case, either the BPPI or the supplier shall give notice to other party of its intension to commence Arbitration procedure as per Indian Arbitration and Conciliation Act, 1996. Such disputes/differences shall be referred to Sole Arbitrator to be appointed by the President/

CEO of BPPI. The venue of Arbitration Shall be at New Delhi. The award published by the Arbitrator shall be final and binding on the parties.

23. APPEAL:

(i) Any Tenderer aggrieved by the order passed by the Tender Accepting Authority under section 10 of the said Act, may appeal to the Department of Pharmaceuticals, Ministry of Chemical and Fertilizer, Government of India within ten days from the date of receipt of order and the Department of Pharmaceuticals, Ministry of Chemical and Fertilizer, Government of India shall dispose the appeal within fifteen days from the date of receipt of such appeal.

(ii) No Appeal shall be preferred while the tender is in process and until tender is finalized and Notification of award is issued by the BPPI.

24. CONTACTING THE BPPI BY THE BIDDER:

(i) No bidder shall contact the *BPPI* on any matter relating to its bid, from the time of bid opening to the time the contract is awarded.

(ii) Any effort by a bidder to influence the *BPPI* in the *Purchaser*'s bid evaluation, bid comparison or contract award decisions may result in rejection of the bidder's bid.

(ii) The bidder shall not make any attempt to establish unsolicited and unauthorized contact with the Tender Accepting Authority, Tender Inviting Authority or Tender Scrutiny Committee after opening of the bids and prior to the notification of award and any attempt by any bidder to bring to bear extraneous pressures on the Tender Accepting Authority, Inviting Authority or Tender Scrutiny Committee, shall be sufficient reason to disqualify the bidder.

(iv) Not withstanding anything contained in clause (iii) above the Tender Inviting Authority or the Tender Accepting Authority, may seek bonafide clarifications from bidders relating to the bids submitted by them during the evaluation of bids.

25. FRAUDULENT AND CORRUPT PRACTICES:

(1)For bidders:

It is purchaser's policy to ensure that suppliers and their authorized representatives/agents observe the highest standard of ethics during the procurement and execution of such contracts. (*In this context, any action taken by a bidder, supplier, contractor, or by their*

authorized representatives/agent, to influence the procurement process or contract execution for undue advantage is improper) In pursuance of this policy, the purchaser;

(a) defines, for the purposes of this provision, the terms set forth below as follows:

(i) "corrupt practice" is the offering, giving, receiving or soliciting, directly or indirectly, of anything of value to influence improperly the actions of another party (*"another party" refers to a public official acting in relation to the procurement process or contract execution]. In this context, "public official" includes staff and employees of other organizations taking or reviewing procurement decisions.*

(ii) "fraudulent practice" is any act or omission, including a misrepresentation, that knowingly or recklessly misleads, or attempts to mislead, a party to obtain a financial or other benefit or to avoid an obligation (*a "party" refers to a public official; the terms "benefit" and "obligation" relate to the procurement process or contract execution; and the "act or omission" is intended to influence the procurement process or contract execution).*

(iii) "collusive practice" is an arrangement between two or more parties designed to achieve an improper purpose, including to influence improperly the actions of another party [*"parties" refers to participants in the procurement process (including public officials) attempting to establish bid prices at artificial, non competitive level]*.

(iv) "coercive practice" is impairing or harming, or threatening to impair or harm, directly or indirectly, any party or the property of the party to influence improperly the actions of a party (*a "party" refers to a participant in the procurement process or contract execution).*

(v) "obstructive practice" is (a) deliberately destroying, falsifying, altering or concealing of evidence material to the investigation or making false statements to investigators in order to materially impede a investigation into allegations of a corrupt, fraudulent, coercive or collusive practice; and/or threatening, harassing or intimidating any party to prevent it from disclosing its knowledge of matters relevant to the investigation or from pursuing the investigation; or acts intended to materially impede the exercise of the purchaser's inspection and audit rights provided for under sub-clause (e) below.

(b) will reject a proposal for award if it determines that the bidder considered for award has, directly or through an agent, engaged in corrupt, fraudulent, collusive, coercive or obstructive practices in competing for the contract in question;

(c) will cancel the contract if the purchaser determines at any time that the bidder, supplier and contractors and their sub contractors engaged in corrupt, fraudulent, collusive, or coercive practices.

(d) will sanction a firm or individual, including declaring in eligible, either indefinitely or for a stated period of time, to be awarded a contract if it at any time determines that the firm has, directly or through an agent, engaged in corrupt, fraudulent, collusive, coercive or obstructive practices in competing for, or in executing, a contract; and

(e) will have the right to inspect the accounts and records of the bidders, supplier, and contractors and their subcontractors/authorized representatives and to have them audited by auditors appointed by the purchaser.

(2) For suppliers:

If the BPPI determines that a Supplier has engaged in corrupt, fraudulent, collusive, coercive or obstructive practices, in competing for or in executing the Contract, then the BPPI may, after giving 7 days notice to the Supplier, terminate the Supplier's engagement under the Contract and cancel the contract, and the procurement will be made at the risk and cost of the supplier besides blacklisting the bidder for 5 years with forfeiture of Security Deposit apart from other penal actions.

(a) For the purposes of this Sub-Clause:

(i) "corrupt practice" is the offering, giving, receiving or soliciting, directly or indirectly, of anything of value to influence improperly the actions of another party;

(ii) "fraudulent practice" is any act or omission, including a misrepresentation, that knowingly or recklessly misleads, or attempts to mislead, a party to obtain a financial or other benefit or to avoid an obligation;

(iii) "collusive practice" is an arrangement between two or more parties designed to achieve an improper purpose, including to influence improperly the actions of another party;

(iv) "coercive practice" is impairing or harming, or threatening to impair or harm, directly or indirectly, any party or the property of the party to influence improperly the actions of a party;

(v) "obstructive practice" is (aa) deliberately destroying, falsifying, altering or concealing of evidence material to the investigation or making false statements to

investigators in order to materially impede a purchaser investigation into allegations of a corrupt, fraudulent, coercive or collusive practice; and/or threatening, harassing or intimidating any party to prevent it from disclosing its knowledge of matters relevant to the investigation or from pursuing the investigation; or (bb)acts intended to materially impede the exercise of the purchaser's inspection and audit rights provided for.

26. JURISDICTION

In the event of any dispute arising out of the tender such dispute would subject to the jurisdiction of the Civil Court within the city of Delhi only.

ANNEXURE -I

Ref. Clause No. 2(e)(i)

DECLARATION

I…….....
Managing Director/Partner/Proprietor of M/s. .....
having its manufacturing or import unit/ registered office at.....do hereby declare that our company/applied items have not been blacklisted/debarred/deregistered either by any State government or Central Government Organization or its drug procurement agencies for the following products quoted in the tender. We are eligible to participate in the tender ref. No. **BPPI/DRUG-029/2015 Dt. 22-09-2015** for the following products.

S. No.	Drug Code	Name of the Drug

Signed.....

Name

Designation

(Company Seal)

To be attested by the Notary

ANNEXURE-II

{Ref : Clause Para No. 2(f)}

(UNDERTAKING ON LETTER HEAD)

I…….....

Managing Director /Partner/Proprietor or authorised signatory of M/s. .....

having its registered office at …….....and its factory premises at ……

…….do declare that I/we have carefully read all the terms and conditions of tender in ref. no. **BPPI/DRUG-029/2015 Dt. 22/09/2015** including Amendment(s) to Tender document (if any) issued by Bureau of pharma public sector undertakings of INDIA, GURGAON, 122016 and accept unconditionally all terms and condition of tender document including Amendment(s) to Tender document (if any).

Signed.....

Name

Designation

(Company Seal)

ANNEXURE -III

Ref. Clause No. 3(i)

DETAILS OF TENDER COST SUBMITTED

We herewith submit the TENDER COST of ₹ **2250/-** in the form of Demand Draft No..... Dated: .....drawn on Bank .....in favour of Bureau of Pharma Public sector Undertakings of India and payable t Gurgaon/Delhi.

Signature & Seal

ANNEXURE -IV

Ref. clause No. 4.1 (i)

DECLARATION

I/We M/s. …… Represented by its Proprietor/Managing Partner /Managing Director having its registered office at …….....and its factory premises at …… ……. ……do declare that I/we have carefully read all the conditions of tender in ref. no. **BPPI/DRUG-029/2015 Dt. 22/09/2015**public sector under taking of INDIA, GURGAON, 122016 and accept all conditions of the Tender.

I/We declare that we possess the valid drug manufacturing licence and GMP Certificate as per schedule M issued by competent authority and complies and continue to comply with the condition lied in schedule M of Drug & cosmetic act, 1940 the rules made there under.

I am / We are aware of the Tender inviting Authority's right to forfeit the Earnest Money Deposit and /or Security Deposit and blacklist me/us for a period of 5 years if, any information furnished by us proved to be false at time the of inspection and not complying the condition as per schedule M of the said Act for a period of five years.

Signature :

Name &Address:

Seal:

To be Notarized.

ANNEXURE -V

Ref. Clause No. 4.1(j)

ANNUAL TURNOVER STATEMENT

The annual Turnover of M/s. .....for the past two years are given below and certified that the statement is true and correct.

Sl.No.	Financial Year	Turnover in Lakhs(Rs.)
1.	2013-14	
2.	2014-15	
3.	2014-15	
TOTAL		Rs.....Lakhs
Average Turnover per annual		Rs.....Lakhs

Date: Signature of Auditor/Chartered Account

Seal: (Name in Capital)

ANNEXURE -VI

Ref. Clause no 4.1 (l) (i)

DECLARATION

I do hereby declare that I will supply the drug and medicines as per the design in enclosures to this Annexure as well as other instruction given in this regard.

Signature of the Tenderer

Name

Designation

(Company Seal)

ANNEXURE –VI(A)

Ref. Clause No. 4.1 (l)(ii)

UNDERTAKING

I / we do hereby declared that I will supply the drugs and medicine by affixing logo on Primary/Secondary/ Tertiary packing for the imported items along with the generic name as per the designs given in enclosures to this annexure as well as other instructions given in this regard.

Signature of the Tenderer

(Name in capital letter with designation)

Enclosure–1 to ANNEXURE -VI AND VI(A) - Refer Clause No .4.1. (l)

DESIGN FOR: Foil / blister of tablet and capsule

1. Foil /Blister should be in minimum two colour i.e. Black & red
2. BPPI Logogram should be placed along with the address as given below
3. BPPI helpline number 1800 180 8080 should be printed
4. Font type should in CALIBIRI format for any type of title name of generic medicines

Manufactured for :

Bureau of Pharma PSUs of India

IDPL Plant complex , Dundahera , Gurgaon 122016 (Haryana)

Or

Manufactured for :

Bureau of Pharma PSUs of India

IDPL Plant complex , Dundahera , Gurgaon 122016 (Haryana)

5. Janaushadhi should be printed in "Inverse red colour" in English and Hindi as

Janaushadhi(English) Jan Aushadhi(In Hindi)

Enclosure – 2 to ANNEXURE –VII & ANNEXURE –VII(A)

Ref. Clause No. 4.1.(l) & Clause No. 13

1. Design for injection for primary packing

a) Vial (5ml or more) should be supplied with the following Jan Aushadhi logogram & BPPI as under:

b) BPPI helpline number 1800 180 8080 should be printed

jan aushadhi
Quality Medicines At Affordable Prices For All

Manufactured for :

Bureau of Pharma PSUs of India

IDPL Plant complex , Dundahera , Gurgaon 122016 (Haryana)

Or

Manufactured for :

Bureau of Pharma PSUs of India

IDPL Plant complex , Dundahera , Gurgaon 122016 (Haryana)

b) Ampoules or Vials less than 5 ml for primary packing

(i) Injection in ampoule or vial (less than 5 ml) should be supplied with BPPI logogram as under (colour should be black)

Manufactured for :

Bureau of Pharma PSUs of India

IDPL Plant complex , Dundahera , Gurgaon 122016 (Haryana)

Or

Manufactured for :

Bureau of Pharma PSUs of India

IDPL Plant complex , Dundahera , Gurgaon 122016 (Haryana)

2. LIQUID:

a) Liquid preparation should by supply with pilfer proof ROPP cap.

b) Bottle cap should not bear the manufacturer's logogram

c) Bottle label should bear JANAUSHDHI logogram as below:

d) BPPI helpline number 1800 180 8080 should be printed

jan aushadhi
Quality Medicines At Affordable Prices For All

Manufactured for :

Bureau of Pharma PSUs of India

IDPL Plant complex , Dundahera , Gurgaon 122016 (Haryana)

3. OINTMENTS / CREAMS

a) Ointment / Cream /Gel /Glass Jar should bear BPPI logo gram as below:

Manufactured for :

Bureau of Pharma PSUs of India

IDPL Plant complex , Dundahera , Gurgaon 122016 (Haryana)

b) BPPI helpline number 1800 180 8080 should be printed

c) Ointment / cream tube should be packed in mono carton (secondary packing) with janaushadhi and BPPI logogram as given below. **Logo in 4 colors will also be accepted.**

jan aushadhi
Quality Medicines At Affordable Prices For All

Manufactured for :

Bureau of Pharma PSUs of India

IDPL Plant complex , Dundahera , Gurgaon 122016 (Haryana)

Enclosure 3 to ANNEXURE –VI(A)

SPECIMEN LABEL FOR MONO CARTON (Secondary Packing)

Rx 10 X 10's
Tablets

Generic Name of Product

jan aushadhi
Quality Medicines At Affordable Prices For All

Note: An additional to statuary requirement under Drug & Cosmetic Act 1940 and rules 1945

Manufactured for :

Bureau of Pharma PSUs of India

IDPL Plant complex , Dundahera , Gurgaon 122016 (Haryana)

ANNEXURE – VII

Ref. Clause No.4.1 (m)

DETAILS OF MANUFACTURING /IMPORTING UNIT

Sl.No.	Details	
1.	Name of the Tenderer & Full Address	
2.	PAN Number	
3.	TIN Number	
4.	Phone Nos.	
5.	Fax	
6.	E-Mail ID	
7.	Date of Inception	
8.	Licence No. & Date	
9.	Issued By	
10.	Valid Upto	

Details of Installed Production Capacity for 1 year

(In Terms of Unit Packs)

S.No.	Details	
1.	**Tablets**	
2.	**Capsules**	
	a) General	
	b) Beta-Lactum	
3.	**Injections**	
	a) Ampoules	
	b) Vials	
	c) I.V. Fluids	
	d) Sterile Powder	
4.	**Liquids**	
	a) Suspension	
	b) Syrups	
	c) Drops	
5.	**Ointment**	
6.	**Powders**	
7.	**Antiseptics / Disinfectants**	
8.	**Name & designation of the authorized Signatory**	
9.	**Specimen signature of the authorized Signatory**	

* The details of manufacturing unit shall be for the premises where items quoted are actually manufactured.

ANNEXURE – VIII

Ref. clause 4.1 (p)

LIST OF ITEMS QUOTED

Sl.No.	Details	
1.	Name of the firm and address (As given in Drug licence)	
2.	Drug Licence No. in form 25 & 28 Or import Licence No.	
3.	Date of issue & validity	
4.	GMP certificate obtained on	
5.	Non-conviction Certificate Obtained on	
6.	Market standing Certificate Obtained on	
7.	Details of Endorsement for all products quoted :	

Sl.No.	Drug Code	Drug Name	Specifications IP/BP/USP	Date of Endorsement obtained from the State Drugs Controller	Whether Endorsement is in Generic or Trade Name
1.					
2.					

Authorised signatory:
Date:

ANNEXURE – IX

Ref. Clause 4.1 (q)

CHECK-LIST

COVER – A

S.No.	Check List	Page no	YES	NO
1.	Checklist - ANNEXURE – IX			
2.	TENDER COST Rs. 2250/- in the form of DD shall be kept in an Envelope as per ANNEXURE-III DD No…….Dated……..issued …….(name of bank)			
3.	EMD Rs.100,000/- in the form of DD shall be kept in an Envelope as per ANNEXURE-X DD No…….Dated……..issued by …….(name of bank) NSIC certificate for exemption if any.			
4.	Documentary evidence for the constitutions of the company / concern			
5.	Duly attested photocopy of License for the Product duly approved by the Licensing Authority for each and every product quoted			
6.	Duly attested photocopy of Import License, if Imported and whole sale Drug license			
7.	The instruments such as power of attorney, Resolution of board etc.,			
8.	Authorization letter nominating a responsible Person of the tenderer to transact the business with the Tender inviting Authority			
9.	Market Standing Certificate issued by the Licensing Authority			
10.	WHO Certificate if any			
11.	Non Conviction Certificate issued by the licensing authority			
12.	Good Manufacturing Practices Certificate			
13.	Latest income tax assessment orders/returns			

	filed.			
14.	ANNEXURE-I (Declaration for eligibility in participating the tender)			
15.	ANNEXURE –II (Acceptance of Terms and conditions)			
16.	ANNEXURE –IV (Declaration for acceptance of tender conditions and compliance of GMP)			
17.	ANNEXURE -V (Annual Turnover Statement for three years.) For loan licensee, turnover of host(actual manufacturer) company also needs to be attached.			
18.	ANNEXURE -VI (Undertaking for embossment of LOGO)			
19	ANNEXURE –VI A(Undertaking for embossment of LOGO)			
20.	ANNEXURE -VII (Details of Manufacturing Unit)			
21.	ANNEXURE -VIII (List of Items quoted without rates) along with soft copy.			
22.	ANNEXURE-X(Notarised Undertaking)			
23	ANNEXURE—XVI (Mandate form)			

Cover "B"

S.No.	Check List	YES	NO
1.	ANNEXURE XVIII duly filled		
3.	Pen drive/compact disc having duly filled ANNEXURES-- XVII		

Name and signature of authorised signatory (with company seal) ……..

ANNEXURE -X

Ref. Clause No. 7.1 & 3(ii)

DETAILS OF E.M.D SUBMITTED

We herewith submit the E.M.D. of ₹ 100,000/- (One Lakh Only) in the form of Demand Draft bearing No..... Dated: .....drawn on.....Bank in favour of Bureau of Pharma Public sector Undertakings of India.

Signature & Seal

ANNEXURE -XI

Ref. Clause No. 7.2

NOTORISED UNDERTAKING

(In 20-Rupees Stamp Paper)

I.....,S/o.....,Proprietor/Partner/ Managing Director of .....(Proprietary Concern/Firm/Company Ltd.) execute this undertaking for myself and on behalf of.....(Proprietary Concern/Firm/Company Ltd.).

And whereas, in pursuant to the conditions in Clause No. 7.2 of the tender, the Earnest Money Deposit can be forfeited by the Tender Inviting Authority in case of violation of any of the conditions and non-performance of the obligation under tender document.

M/s.....

For Self and Firm/Company Ltd.

(Signature and Seal)

Witness:-

(1).....

(2).....

Annexure – XII

Clause no. 8.1 & 8.2

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKING OF INDIA, GURGAON

TENDER FOR THE SUPPLY OF MEDICINES REFERENCE BPPI/DRUGS-29 DT 22/09/2015

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Pack Size	Packing per carton specification	Approx. tender qty.
1	14	IBUPROFEN 400 MG + PARACETAMOL 325 MG	15's	15x10's	15'sx10x100	1000000
2	15	IBUPROFEN 200MG FILM COATED	10x10	10x10's	10'sx10x100	3,00,000
3	16	IBUPROFEN 400 MG	15's	15x10's	15'sx10x100	1000000
4	89	CO-TRIMOXAZOLE TABLETS IP (160 MG + 800 MG)	10's	1x10's	1'sx10x100	3,00,000
5	165	CIPROFLOXACIN INJECTION IP 2MG/ML	100 ml	1x10's	100mlX20	5,00,000
6	191	FAMOTIDINE TABLETS IP 20 MG	14's	14x10's	14'sx10x100	3,00,000
7	194	HYOSCINE 10 MG	10's	10x10's	10'sx10x100	10,00,000
8	201	METRONIDAZOLE 200 MG FILM COATED	10's	10x10's	10'sx10x100	3,00,000
9	202	METRONIDAZOLE 400 MG	10's	10x10's	10'sx10x100	10,00,000
10	255	SALBUTAMOL INHALATION IP 100 µg 200 MD	1's	1x10's	1'sx10x100	2,00,000
11	256	SALBUTAMOL 2 MG	10's	10x10's	10'sx10x100	10,00,000
12	329	PREDNISOLONE TABLETS IP 5 MG	15's	15x10's	15'sx10x100	7,50,000
13	333	DEXAMETHASONE 0.5 MG TABS	10's	10x10's	10'sx10x100	10,00,000
14	334	DEXAMETHASONE INJECTION IP 4 MG/ML	2ML	2MLx10's	2MLx10x100	10,00,000
15	345	GENTAMYCIN 0.3% W/V	5ML	5MLx10's	5ML'sx10x100	5,00,000
16	392	GRISEOFULVIN TABLETS IP 250 MG	10's	10x10's	10'sx10x100	5,00,000
17	408	BENZYLPENICILLIN INJ IP 0.6 MILLION UNITS	VIAL	1x10's	1'sx10x100	2,00,000
18	409	BENZYLPENICILLIN INJ IP 1.2 MILLION UNITS	VIAL	1x10's	1'sx10x100	2,00,000
19	492	SULFASALAZINE TABLETS EC BP 500 MG	10's	10x10's	10'sx10x100	2,00,000
20	514	CHYMOTRYPSIN + TRYPSIN (1:6) TABLETS 100K AU	20's	20'Sx10	20'sx10x100	2,00,000
21	600	Paracetamol IP…170 mg. Phenylephrine Hydrochloride IP…2.5 mg., Dextromethorphan Hydrochloride IP…5 mg., Chlorpheniramine Maleate IP…1.5 mg. In a flavoured syrupy base…q.s.	60 ml.	60 ML x 10	60 ML x 10 x 10	5,00,000
22	601	Disulfiram IP 500 mg	4s	10'sx10	10'sx10x100	1,50,000
23	602	Cold & Flu Tab N/F (Nimesulide 100 mg Paracetamool 500 mg Cetirizine Hydrochloride 5 mg Phenylephrine Hydrochloride 5 mg Caffeine (Anhydrous) 25 mg	10's	10'sx10	10'sx10x100	10,00,000
24	603	Cetirizine Dihydrochloride IP…5 mg., Phenylephrine Hydrochloride IP…10 mg., Paracetamol IP…325 mg.	10s	10'sx10	10'sx10x100	10,00,000
25	604	Levocetrizine HCL 5mg, Phenylephrine HCL 5mg, Ambroxol HCL 30mg, Paracetamol 325mg	10's	10'sx10	10'sx10x100	10,00,000
26	605	Etofylline BP…..200 mg., Salbutamol Sulphate IP equivalent to Salbutamol .4 mg, Bromhexine Hydrochloride IP…..8 mg.	10s	10'sx10	10'sx10x100	10,00,000
27	606	Cyproheptadine 4 mg	10's	10'sx10	10'sx10x100	5,00,000
28	607	Beclamethasone Dipropionate..0.025% w/, Neomycin Sxulphate..0.5% w/w (3500 Unit /G) Chlorocresol 0.1% w/w	15 gms.	15 GMx20	15 gm x 20x 20	10,00,000
29	608	Betamethasone 0.05% w/w + Salicylic acid 3% w/w	20 Gm	20 GMx20	20 gm x 20x 20	5,00,000

Annexure – XII

Clause no. 8.1 & 8.2

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKING OF INDIA, GURGAON

TENDER FOR THE SUPPLY OF MEDICINES REFERENCE BPPI/DRUGS-29 DT 22/09/2015

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Pack Size	Packing per carton specification	Approx. tender qty.
30	609	Silver Nitrate 0.20 % w/w, Chlorhexidine Gluconate Solution 0.20%, Preservative: Chlorocresol 0.12 % w/w, In a Cream Base q.s.	15 Gms Tube	15 GMx20	15 gm x 20x 20	7,50,000
31	610	Cold Suspn.N/F (Paracetamol 125 mg+ Phenylephrine Hydrocloride IP 5mg + Cetirizine Dihydrocloride IP 2mg syrup	60ml	60 ML x 10	60 ML x 10 x 10	5,00,000
32	611	Cyproheptadine, Hydrochloride(anhydrous) IP..2 mg.In a flavoured syrup base ….q.s.	200 ml.	1's	200 ML X 20	5,00,000
33	612	Dusting Powder (Povidone 5% Powder	10 Gm Container	10 gmX20	10 gm x 20x 20	5,00,000
34	613	Diclofenac Potassium BP 50 mg + Paracetamol 325 mg + Serratiopeptidase 10 mg	10's	10'sx10	10'sx10x100	5,00,000
35	614	Ear Drops (Paradichlorobenzene 2%+Benzocaine 2.7%+Chlorbutol 5%+Turpentine Oil15%	10ml	10 MLX10	10 MLX10X20	5,00,000
36	615	Clobetasol Propionate USP…0.05 % w/w, Neomycin Sulphate IP equivalent to Neomycin…0.5 % w/w, Miconazole Nitrate IP…2.0 % ww, Zinc Sulphate IP…2.0 % w/w.	10 gms.	10 gmX20	10 gm x 20x 20	5,00,000
37	616	Celecoxib 100 mg capsules	10's	10'sx10	10'sx10x100	2,00,000
38	617	Celecoxib 200 mg capsules	10's	10'sx10	10'sx10x100	2,00,000
39	618	Paracetamol IP 450mg Bromhexine Hydrochloride 8mg Chlorpheniramine maleate 2mg Phenylephrine Hydrochloride 10mg Guaiphenesin 100mg	10's	10'sx10	10'sx10x100	5,00,000
40	619	Cough Paed. Syrup Dextromethorphan Hydrobromide IP 5 mg. + Bromhexine HCl 4mg+ Phenylpropanolamine HCl 10 mg+ Menthol IP 0.75 mg / 5ml	60 ml Bottle	60 ML x 10	60 ML x 10 x 10	5,00,000
41	620	BromhexineHCl+ Dextrometh orphan +Ammonium Chloride+Menthol	100ml Bottle	100 ML X6	100 MLX6X20	5,00,000
42	621	Iron & Zinc (Carbonyl Iron 50 mg+ Zinc Sulphate Monohydrate USP 61.8 mg equivalent to Elemental Zinc 22.5 mg + Folic Acid IP 0.5mg	15's	15'sx10	15'sx10x100	10,00,000
43	622	Cough lozenges Ginger / Lemon (2,4 Diclorobenzyl alcohol1.2 mg + Amylmetacresol 0.6 mg in Ginger /Lemon flavour	8's	8'sx10	8'sx10x100	10,00,000
44	623	Cough lozenges Regular 2,4 - Diclorobenzyl Alcohol 1.2 mg, Amylmetacresol BP 0.6 mg	8's	8'sx10	8'sx10x100	10,00,000
45	624	Cough Expectorant Chlorpheniramine Maleate 2.5 mg + Ammonium chloride 125mg + Sodium Citrate 55mg	100ml Bottle	100 ML X6	100 MLX6X20	10,00,000
46	625	Cough Tablets Bromhexine Hydrochloride 8.00 mg Phenylephrine Hydrochloride 5.00 mg	15's	15'sx10	15'sx10x100	5,00,000
47	626	Dandruf Shampoo KETOCONAZOLE IP SHAMPOO 1% W/V	100ml Bottle	100 ML X6	100 MLX6X20	5,00,000
48	627	Etophylline IP 115mg + Theophylline 35mg	10's	10'sx10	10'sx10x100	5,00,000
49	628	Etophylline IP 231mg. + Theophylline 69mg	10's	10'sx10	10'sx10x100	5,00,000
50	629	Inhalent Softgel Caps. (Camphor 25 mg + Clorothymol 5 mg + Eucalyptus 130 mg + Menthol 55 mg + Turpentine	10's	10'sx10	10'sx10x100	5,00,000

Annexure – XII

Clause no. 8.1 & 8.2

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKING OF INDIA, GURGAON

TENDER FOR THE SUPPLY OF MEDICINES REFERENCE BPPI/DRUGS-29 DT 22/09/2015

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Pack Size	Packing per carton specification	Approx. tender qty.
		oil 110 mg				
51	630	laxative Suspension Liqid Paraffin 3.75ml+Milk of Magnesia 11.25ml)	170ml Bottle	1's	170 ML X 20	10,00,000
52	631	Ethamsylate B.P 500 mg.	10's	10'sx10	10'sx10x100	3,00,000
53	632	Ethamsylate B.P 250 mg.	10's	10'sx10	10'sx10x100	3,00,000
54	633	Anti-acne Gel Adapalene BP…0.1 % w/w, Clindamycin Phosphate USP equivalent to Clindamycin…1% w/w, Methyl Paraben IP…0.1 % w/w, Phenoxyethanol BP…0.25 % w/w	15 gms.Tube	15 GMx20	15 gm x 20x 20	5,00,000
55	634	Clobetasol Proppionate BP…0.05 % w/w, Neomycin Sulhate IP…0.50 % w/w., Miconazole Nitrate IP…2.00 % w/w, Chlorhexidine Gluconate SolutionIP…0.20 %., Chlorocresol IP(as preservative) 0.10 % w/w	20 gms.	20 GMx20	20 gm x 20x 20	2,00,000
56	635	Clobetasol Propionate BP…0.05% w/w, Neomycin Sulphate IP …0.50% w/w.Miconazole Nitrate IP….2.00% w/w, Chlorhexidine Gluconate Solution…..0.20%, Chlorocresol IP (as preservative) 0.10% w/w	10 gms tube	10 gmX20	10 gm x 20x 20	2,00,000
57	636	Ferric Ammonium Citrate 200 mg, Cyanocobalamin 7.5 mcg, Folic acid 0.5 mg, Zinc Sulphate 7 mg, Pyridoxine Hcl 1.5 mg, Sorbitol 70%	225 ml	1's	225 ML X 20	5,00,000
58	637	Aceclofenac 100 mg + Paracetamol 325 mg + Chorzoxazone 250 mg film coated tab.	10's	10'sx10	10'sx10x100	3,00,000
59	638	Aceclofenac 100 mg Paracetamol 325 mg Serratiopeptidase 15 mg	10's	10'sx10	10'sx10x100	5,00,000
60	639	Mucodilator Expectorant Terbutaline Sulphate 1.25 mg, Bromhexine 4 mg, Guaiphenesin 50 mg, Menthol 2.5 mg per 5 ml	100 ml	100 ML X6	100 MLX6X20	10,00,000
61	640	Nimesulide 1% W/W Gel	20 Gm tube	20 GMx20	20 gm x 20x 20	10,00,000
62	642	Triprolidine Hydrochloride 2.5mg Phenylephrine Hydrochloride 10mg Paracetamol 500 mg	10'S	10'sx10	10'sx10x100	5,00,000
63	643	Paracetamol 125mg+ CPM 1 mg + Sodium Citrate 60mg in a flavour syrup base	60 ml Bottle	60 ML x 10	60 ML x 10 x 10	2,00,000
64	644	Phenylephrine Hydrochloride 5.00mg Chlorpheniranmine Maleate 2.00mg Drops	15ml Bottle	15 MLX20	15 MLX20X20	5,00,000
65	645	Nimesulide 100mg, Paracetamol 325mg, Chlorzoxazone 375mg	10's	10'sx10	10'sx10x100	10,00,000
66	646	Diclofenac diethylamine BP 1.116% (equivalent to diclofenac sodium 1.0%, Linseed oil BP 3.0% + Methyl Salicylate IP 10.0%, Capsiacin USP 0.025%, Menthol IP 0.025%, Benzyl alcohol IP 1.0% (as preservative) In a gel base q.s.	30 Gm	30gmX20	30 gm x 20x 20	10,00,000
67	647	Diclofenac Di + Menthol 5%+ Oleum 3% + Methyl Salicylate	20 Gm	20 GMx20	20 gm x 20x 20	10,00,000
68	648	Dethylamine BP…1.16 %, Linseed Oil BP…3 % w/w, Methyl Salicylate IP…10 % w/w, Menthol IP…5 % w/w, Excipients and Propellant q.s. to…100 % w/w Spray	35 gms.	35gmX20	35 gm x 20x 20	5,00,000
69	649	Dicyclomine 10mg + Act. Dimethicone 40mg per ml	10ml Bottle	10 MLX10	10 MLX10X20	5,00,000

Annexure – XII

Clause no. 8.1 & 8.2

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKING OF INDIA, GURGAON

TENDER FOR THE SUPPLY OF MEDICINES REFERENCE BPPI/DRUGS-29 DT 22/09/2015

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Pack Size	Packing per carton specification	Approx. tender qty.
70	650	Mefenamic Acid 500mg+Paracetamol 450 mg	10's	10'sx10	10'sx10x100	10,00,000
71	651	Paracetamol IP…125 mg., Mefanamic Acid IP…50 mg., in a flavoured syrupy base…q.s.	60 ml.	60 ML x 10	60 ML x 10 x 10	500000
72	652	Dicyclomine 10mg + Mefenamic 250 mg	10's	10'sx10	10'sx10x100	10,00,000
73	653	Syrup Vitamin D3 200 IU + Vitamin B12 2.5 mcg + Calcium Phosphate eq. to elemental Calcium 82 mg / 5 ml	225 ml	1's	225 ML X 20	3,00,000
74	654	Enyme Syrup Cardamom Flavour Pepsin 7.5 mg + Fungal Diastase 12.5 mg / 5 ml	200 ml	1's	200 ML X 20	5,00,000
75	655	Enyme Syrup Mix Fruit Flavour Pepsin 7.5 mg + Fungal Diastase 12.5 mg / 5 ml	200 ml	1's	200 ML X 20	5,00,000
76	656	Enzyme Drops Pepsin (1:3000) 5 mg + Fungal Diastase (1:1200) 33.33 mg/ml	15ML	15 MLX20	15 MLX20X20	5,00,000
77	657	Hydroquinone 2.0% w/w + Tretinoin 0.025% w/w + Mometasone Furoate 0.1% w/w in a cream base q.s	15 gm	15 GMx20	15 gm x 20x 20	5,00,000
78	658	Chlorhexidine Gluconate 0.3% v/v + Cetrimide 0.6% w/v	100 ml	100 ML X6	100 MLX6X20	5,00,000
79	659	Chlorhexidine Gluconate 0.3% v/v + Cetrimide 0.6% w/v	200 ml	1's	200 ML X 20	3,00,000
80	660	Cetrimide 0.5% + Vit. E Acetate 0.1% + Glycerin q.s	75 gms.	75gmX20	75 gm x 20x 20	3,00,000
81	661	Gama Benzene Hexachloride 1 % w/v + Cetrimide 0.1% w/v	100ml	100 ML X6	100 MLX6X20	3,00,000
82	662	Gama Benzene Hexachloride 1 % w/v + Cetrimide 0.1% w/v	200ML	1's	200 ML X 20	3,00,000
83	663	Junior Cough Syrup Chlorpheniramine Maleate 2 mg + Dextromethorphan Hydrobromide 10 mg + Phenylephrine HCl 5 mg / 5 ml	100 ml	100 ML X6	100 MLX6X20	5,00,000
84	664	Mouth Ulcer Gel (Choline Salicylate sodium 9% w/v, Benzalkonium Chloride 0.01% w/w)	10 gm	1's	10 gm x 20x 20	5,00,000
85	665	BCOMPLEX PLUS Each capsule contains - Thiamine mononitrate IP-10mg,Riboflavin IP -10 mg,Pyridoxine HCl IP-3mg,Vitamin B 12 IP - 5mcg,Niacimnamide IP - 50mg,Calcium Pantothenate IP-12.5mg,Flolic Acid IP - 1mg, Ascorbic Acid IP- 150mg	10's	10'sx10	10'sx10x100	10,00,000
86	666	Pheniramine Maleate I.P. 22.75mg,Methyl Paraben(as preservative) I.P. 0.135% w/v, Propyl Paraben(as preservative) I.P. 0.015% w/v, Water for injection I.P. q.s.	2ml	2 ml x 10	2 ml x 10 x 50	5,00,000
87	667	Paracetamol I.P. 125 mg: Promethazine HCl I.P. 5 mg	15ml	15 MLX20	15 MLX20X20	5,00,000
88	668	Multivitamin Drops : Vitamin A(as Palmitate)IP 2500 IU, Vitamin E Acetate IP 2.5 IU,Vitamin D3 IP 200 IU,Ascorbic Acid IP 40mgThiamine Hydrochloride IP 1mg,Riboflavine Sodium Phosphate IP 1.5mg,Niacinamide IP 10mg,D-Panthenol IP 3mg,D-Botin BP 50mcg ,Lysine	15ml	15 MLX20	15 MLX20X20	3,00,000
89	669	Syrup - Cefuroxime 125mg(asCefuroxime Axetil USP)	30ml	30 MLX20	30 MLX20X20	2,00,000
90	670	Diacerein 50 mg +Methylsulphonylmethane 200 mg + Glucosamine Sulphate 500 mg	10's	10'sx10	10'sx10x100	3,00,000
91	671	Diacerein 50 mg + Glucosamine Sulphate 500 mg	10's	10'sx10	10'sx10x100	3,00,000

Annexure – XII

Clause no. 8.1 & 8.2

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKING OF INDIA, GURGAON

TENDER FOR THE SUPPLY OF MEDICINES REFERENCE BPPI/DRUGS-29 DT 22/09/2015

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Pack Size	Packing per carton specification	Approx. tender qty.
92	672	Mometasone Furoate 0.1 % w/w	15gm	15 GMx20	15 gm x 20x 20	3,00,000
93	673	Biotin 10 mg	10's	10'sx10	10'sx10x100	3,00,000
94	674	Sitaglptin 100 mg	10's	10'sx10	10'sx10x100	2,00,000
95	675	Sitaglptin 50 mg	10's	10'sx10	10'sx10x100	2,00,000
96	676	Trimcelone Acetonide 0.1 % Mouth Ulcer gel	10gm	10gmX20	10 gm x 20x 20	5,00,000
97	677	Flupentixol 0.5 mg	10's	10'sx10	10'sx10x100	5,00,000
98	678	levodopa & Carbidopa tab	10's	10'sx10	10'sx10x100	5,00,000
99	679	Nalidixic Acid 500 mg	10's	10'sx10	10'sx10x100	5,00,000
100	680	Finaestride 5 mg	10's	10'sx10	10'sx10x100	5,00,000
101	681	Phenazopyridine Hcl 100mg tab	10's	10'sx10	10'sx10x100	5,00,000
102	682	Rabeprazole 20mg + Domperidone 10mg	10's	10'sx10	10'sx10x100	2,000,000
103	683	Rabeprazole Sodium ip 20mg + Itopiride HCL 150mg	10's	10'sx10	10'sx10x100	5,00,000
104	684	Pantoprazole 40mg + Domperidone 30mg S.R.	10's	10'sx10	10'sx10x100	5,00,000
105	685	Pantoprazole 40mg + Itopride 150mg S.R.	10's	10'sx10	10'sx10x100	5,00,000
106	686	Magaldrate 400 mg + Simethiocone 20 mg	170 ml	1's	170 ML X 20	3,00,000
107	687	Lactulose 10 gm/ 15 ml	200 ml	1's	200 ML X 20	5,00,000
108	688	Nitroglycerine Injection 5mg/ ml	10 ml Vial	10 MLX10	10 MLX10X20	3,00,000
109	689	Clotrimazole 100 mgVaginal Tab	10's	10'sx10	10'sx10x100	5,00,000
110	690	Timolol Maeleate 0.5 % Eye Drops	10 ml Vial	10 MLX10	10 MLX10X20	300,000
111	691	Ofloxacin Eye Drops	10 ml Vial	10 MLX10	10 MLX10X20	5,00,000
112	692	Olopattadine Eye Drops	10 ml Vial	10 MLX10	10 MLX10X20	3,00,000
113	693	Tropicamide Eye Drops	10 ml Vial	10 MLX10	10 MLX10X20	300,000
114	694	Tobramycin Eye Drops	10 ml Vial	10 MLX10	10 MLX10X20	5,00,000
115	695	Polymyxin B sulphate BP 5000 iu , Chloramphenicol IP 4mg Phenulmercuiric intrate IP	5 ml	5 ml x 10	5 ml x 10 x 50	3,00,000
116	696	Polymyxin B sulphate BP 5000 iu , Chloramphenicol IP 4mg ,Dexamethasone sodium phosphate IP 1 mg Phenulmercuiric intrate IP	5 ml	5 ml x 10	5 ml x 10 x 50	3,00,000
117	697	Sulfacetamide eye drop 10 %	10 ml	10 MLX10	10 MLX10X20	10,00,000
118	698	Sulfacetamide eye drop 20 %	20 ml	20 MLX20	15 MLX20X20	10,00,000
119	699	Acyclovir Eye Ointment	5gm	5gmX20	5 gm x 20x 20	3,00,000
120	700	Ketamine Hydrochloride 10 mg/ml Injection	20ml Vial	20 ml x 10	20 ml x 10 x 50	3,00,000
121	701	Pilocar 2 % eye drop	10 ml Vial	10 MLX10	10 MLX10X20	3,00,000
122	702	Haloperidol 0.5 mg	10's	10'sx10	10'sx10x100	2,00,000

Annexure – XII

Clause no. 8.1 & 8.2

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKING OF INDIA, GURGAON

TENDER FOR THE SUPPLY OF MEDICINES REFERENCE BPPI/DRUGS-29 DT 22/09/2015

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Pack Size	Packing per carton specification	Approx. tender qty.
123	703	Nimsulide 100 mg + Serratiopeptidae 15 mg	10's	10'sx10	10'sx10x100	3,00,000
124	704	Cephalexin 125mg/5ml dry syrup	30ml	30 ml x 10	30 ml x 10 x 50	3,00,000
125	705	Levofloxacin 500 mg INFUSION / IV	100ml	100 ML X6	100 MLX6X20	5,00,000
126	706	Cefpodoxime proxetil 50 mg DS dry syrup	30ml	30 ml x 10	30 ml x 10 x 50	2,00,000
127	707	Piroxicam 10 mg tablets	10's	10'sx10	10'sx10x100	5,00,000
128	708	Piroxicam 20 mg btablets	10's	10'sx10	10'sx10x100	5,00,000
129	709	Piroxicam 20 mg with bezyl alcohol injection	1ml	1 ml x 10	1 ml x 10 x 50	3,00,000
130	710	Piroxicam 40 mg with bezyl alcohol injection	2ml	2 ml x 10	2 ml x 10 x 50	3,00,000
131	711	Ofloxacin 50mg+Ornidazole125mg+Simethicone 10 mg	60ml	60 ML x 10	60 ML x 10 x 10	3,00,000
132	712	Paracetamol DS syrup /250 mg	60ml	60 ML x 10	60 ML x 10 x 10	5,00,000
133	713	Glibenclamide 5mg + MetforminHcl 500 mg	10's	10'sx10	10'sx10x100	5,00,000
134	714	Ofloxacin 200mg+Ornidazole500mg infusion	100 ml	100 ML X6	100 MLX6X20	5,00,000
135	715	Glycerin ip 98%w/w	50 gm	50gmX20	50 gm x 20x 20	5,00,000
136	716	Urea IP 1 % + Salicylic Acid IP 1% w/w Zinc Sulphate 0.1 % w/w	10 gm	10 gmX20	10 gm x 20x 20	3,00,000
137	717	Etodolac tablets 300 USP mg	10's	10'sx10	10'sx10x100	3,00,000
138	718	Escitalopram 10mg with Clonazepam 0.5mg	10's	10'sx10	10'sx10x100	3,00,000
139	719	Ringer Lactate IV fluid beg self collapsible closed system	100 ml	100 ML X6	100 MLX6X20	10,00,000
140	720	Ringer Lactate I V fluid beg self collapsible closed system	500ml	1's	500MLX10	10,00,000
141	721	Water for Injection amp polypack	2ml	2 ml x 10	2 ml x 10 x 50	10,00,000
142	722	Water for Injection amp polypack	5ml	5 ml x 10	5 ml x 10 x 50	20,00,000
143	723	Water for Injection amp polypack	10ml	10 MLX10	10 MLX10X20	10,00,000
144	724	Whey Peptide based Enteral nutrition Per 100gm Energy 464 Kcal Protin 18.5gm Fat 17 gm MUFA 1.19Gm PUFA 2.58, Carbs 59.40gm Vit A / D/ E/K/C/B1/ B2/NIACIN/B6/Folic Acid/ Pantothenic Acid / B12/ Biotin/ Minerals and Choline Taurine & Carnitine	200 gm Tin	1's	200GMX20	3,00,000
145	725	Dextrose 5 %	500ml IV fluid beg self collapsible closed system	1's	500MLX20	10,00,000
146	726	Dextrose 10 %	500ml IV fluid beg self collapsible closed system	1's	500MLX20	10,00,000

Annexure – XII

Clause no. 8.1 & 8.2

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKING OF INDIA, GURGAON

TENDER FOR THE SUPPLY OF MEDICINES REFERENCE BPPI/DRUGS-29 DT 22/09/2015

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Pack Size	Packing per carton specification	Approx. tender qty.
147	727	Dextrose with Saline 5% + 0.45%	500ml I V fluid beg self collapsible closed system	1's	500MLX20	10,00,000
148	728	Dextrose with Saline 5% + 0.9%	500ml I V fluid beg self collapsible closed system	1's	500MLX20	10,00,000
149	729	Dextrose with Saline 5% + 0.22%	500ml I V fluid beg self collapsible closed system	1's	500MLX20	10,00,000
150	730	Dextrose with Saline (N/2 DNS 5% + 0.45%	500ml IV fluid glass/ plastic container	1's	500MLX20	10,00,000
151	731	Dextrose with Saline (N/4 DNS) 5% + 0.22%	500ml IV fluid glass/ plastic container	1's	500MLX20	10,00,000
152	732	Normal Saline (NS) 0.9% w/v	500ml IV fluid glass/ plastic container	1's	500MLX20	10,00,000

ANNEXURE -XIII

Ref. Clause No.10.1

Performance Security Bank Guarantee

(unconditional)

To: Bureau of Pharma Public Sector Undertakings of India, (Name of purchaser) IDPL Complex, Old-Delhi-Gurgaon Road, Dundehera, Gurgaon 122016 (Haryana)

WHEREAS……(Name of the Supplier) herein called "the Supplier" has undertaken, in pursuance of Tender BPPI/DRUGS/029/2015 dated **22.09.2015** to supply of **Drugs and Medicines for the year 2015-17,** (Description of Goods and Services) hereinafter called "the Contract".

AND WHEREAS it has been stipulated by you in the said Contract that the Supplier shall furnish you with a Bank Guarantee for the sum specified therein as security for compliance with the Supplier's performance obligations in accordance with the Contract.

AND WHEREAS we have agreed to give the Supplier a Guarantee

THEREFORE WE hereby affirm that we are Guarantors and responsible to you, on behalf of the Supplier, upto a total of …….(Amount of the Guarantee in Words and Figures) and we undertake to pay you, upon your first written demand declaring the Supplier to be in default under the Contract and without cavil or argument., any sum or sums within the limit of ……..(Amount of the Guarantee in Words and Figures) as aforesaid, without your needing to prove or to show grounds or reasons for your demand or the sum specified therein.

This guarantee is valid until the …….day of……2017.

Signature and Seal of Guarantors

……

……

……

Date……..2015

Address……

……

ANNEXURE-XIV

Ref. Clause No.10.2

AGREEMENT

THIS AGREEMENT made the ……day of ……..2015 Between Bureau of Pharma Public Sector Undertakings of India, IDPL Complex, Old-Delhi Gurgaon Road, Dundahera, Gurgaon 122016 (Haryana)

(Name of purchaser) of (Country of Purchaser) (here in after "the Purchaser") of the one part and ……(Name of Supplier) of ……(City and Country of Supplier) (herein after called "the Supplier") of the other part :

WHEREAS the Purchaser is desirous that certain Goods and ancillary services viz; Supply of Drugs and Medicines in the tender Reference No. BPPI/DRUGS/029/2015 (Brief Description of Goods and Services) and has accepted a bid by the Supplier for the supply of those goods and services for the sum of …….(Contract Price in Words and Figures((hereinafter called "the Contract Price").

NOW THIS AGREEMENT WITNESSETH AS FOLLOWS:

1. In this Agreement words and expressions shall have the same meanings as are respectively assigned to them in the Conditions of Contract referred to, and they shall be deemed to form and be read and construed as part of this agreement.

2. The following documents shall be deemed to form and be read and construed as part of this Agreement, viz

    a. The Letter of Acceptance issued by the purchaser.

    b. The Notice Inviting Tender

    c. The supplier's bid including enclosures, annexures, etc.

    d. The Terms and Conditions of the Contract

    e. The Schedule of Requirement

    f. The Technical Specification

g. Any other document listed in the supplier's bid and replies to queries, clarifications issued by the purchaser, such confirmations given by the bidder which are acceptable to the purchaser and the entire Addendum issued as forming part of the Contract.

3. In consideration of the payments to be made by the Purchaser to the Supplier as hereinafter mentioned, the Supplier hereby covenants with the Purchaser to provide, the goods and services and to remedy defects therein in conformity in all respects with the provisions of the Contract. .

4. The purchaser hereby covenants to pay the Supplier in consideration of the provision of the goods and services and the remedying of defects therein, the Contract Price or such other sum as may become payable under the provisions of the Contract at the times and in the manner prescribed by the Contract.

Brief particulars of the goods and services which shall be supplied / provided by the Supplier are as under:

S.No.	Drug Code	Name of Product	UNIT	Tender Qty in Unit* (A)	Unit Price (B)	CST against form C/VAT in % (C)	Total (B+C) (D)	Total value inclusive CST/VAT (A x D)
Total Contract Value								

*** Tender quantity indicated here is tentative and may vary subjected to various terms and conditions of the tender.**

*** Excise duty as applicable on MRP to be intimated by BPPI at the time of placing orders will be payable as per prevailing excise duty rates.**

DELIVERY SCHEDULE

Supply shall all complete within 60th day from the date of issue of Ist purchase order and within 45th day from the date of issue of subsequent purchase order.

IN WITNESS where of the parties here to have caused this Agreement to be executed in accordance with their respective laws the day and year first above written.

Signed, Sealed and Delivered by the

Said…….(For the Purchaser)

Name –

Address - IDPL Complex, Old-Delhi-Gurgaon Road, Dundehera, Gurgaon 122016 (Haryana)

Designation –Director (Operation)

In the presence of witness……

Signature

Name

Address- IDPL Complex, Old-Delhi-Gurgaon Road, Dundehera, Gurgaon 122016 (Haryana)

Designation – Executive (Procurement)

Signed, Sealed and Delivered by the

Said…….(For the Supplier)

Name

Address

Designation

In the presence of witness ……..

Signature

Name

Address Designation

ANNEXURE-XV

Ref. Clause No.14.1

SCHEDULE FOR PACKAGING OF DRUGS AND MEDICINES

GENERAL SPECIFICATIONS

1. Strips of Aluminum foils should be gauge 04.
2. Aluminum foils s back material for blisters should be gauge 025.
3. The rigid PVC used in blister packing should be of not less than 250 micron
4. All glass bottles should be new neutral glass. Pet bottles so accepted as per drug laws stipulation.
5. Ointments should be packed in lacquerized Aluminum Tubes or Lami tubes.
6. Small Tablets packed in blisters should be packed to facilitate easy removal of the tablet without breaking / crushing.
7. Specification of outer cartons are as given in the Schedule (Annexure-XIV)
8. In case of any conflict between Carton specifications and packets per carton specification the specification of the packets / carton shall prevail.
9. All plastic containers should be made of virgin grade plastics
10. Injection in vials should have a flip-off seals.
11. The strips shall be aluminum strip / blisters with aluminum foil back.
12. The minimum diameters of each tablets should be of 6.4mm
13. The outer carton should be of white board with a minimum of 300 GSM with **Gloss laminated/UV Varnished** packing for the strips, blisters, ointments, creams etc. and for ampoules and vials should be with white board of 350GSM.
14. All liquid oral preparations to be provided with a measuring plastic cup, fitted over the cap of the bottle.
15. All primary packaging should have BPPI toll free number 1800 180 8080

(Schedule)

1.	**CORRUGATED BOXES(Liquid)**
	1. No corrugate package should weigh more than 15 kgs (i.e. product + inner carton + corrugated box). 2. All Corrugated boxes should be of `A' grade paper i.e. Virgin. 3. All items should be packed only in first hand boxes only.

2.	**FLUTE**
	The corrugated boxes should be of narrow flute.
3.	**JOINT**
	Every box should be preferably single joint and not more than two joints.
4.	**STITCHING**
	Every box should be stitched using pairs of metal pins with an interval of two inches between each pair. The boxes should be stitched and not joined using calico at the corners.
5.	**FLAP**
	The flaps should uniformly meet but should not over lap each other. The flap when turned by 45 - 60◦ should not crack.
6.	**TAPE**
	Every box should be sealed with gum tape running along the top and lower opening.
7.	**CARRYSTRAP:** Every box should be strapped with two parallel nylon carry straps (they should intersect).
8.	**LABEL**
	The product label on the carton should be large at least 15 cms x 10 cms dimension. It should carry the correct technical name, strength of the product, date of manufacturing, date of expiry, quantity packed and net weight of the box.
9.	**OTHERS**
	No box should contain mixed products or mixed batches of the same product.

II. SPECIFICATION OF CORRUGATED BOXES HOLDING TABLETS / CAPSULES / PESSARIES

(1) The box should not weigh more than 7-8 kgs. The grammage of outer box should be 150 gsm and inside partition / lining should be 120 gsm.

(2) The box should be of 5 ply with bursting strength of 9 Kg / Cm2

III. SPECIFICATIONS OF CORRUGATED BOXES FOR OINTMENT / CREAM / GELS PACKED IN TUBES:

(1) No corrugate box should weigh more than 7-8 Kgs.

(2) Every Ointment tube should be individually packed in carton and then packed in 20's in a grey board box, which may be packed in a corrugated box.

(3) Grammage: Outer box should be 150 gsm inside partition /

Lining should be 120gsm.

IV. SPECIFICATIONS OF CORRUGATED BOXESFOR INJECTABLE (IN VIALS AND AMPOULES)

(1) Vials may be packed in corrugated boxes weighing upto 15 Kgs. Ampoules should be packed in C.B weighing not more than 8 kgs.

(2) C.B. for vials should be of 150 gsm (outer box should be 150 gsm and inside partition / lining should be 120 gsm) and 7 ply, while CB. For ampoules should be of 150 gsm (outer box should be 150 gsm and inside partition / lining should be 120 gsm) and 5 ply.

(3) Bursting strength for CB boxes for

i. Vials : Note less than 13 Kg/Cm2

ii. Amp : Note less than 9 Kg/Cm2

(4) In the case of 10 ml Ampoules 100 or 50 ampoules may be packed in a grey board box. Multiples of grey board boxes packed in CB. In case of ampoules larger than 10 ml only 25 ampoules may be packed in a grey board box with partition.

(5) If the vial is packed in individual carton, there is no necessity for grey board box packing. The individual carton may be packed as such in the CB with center pad.

(6) In case of ampoules every grey board box should carry 5 amps. Cutters placed in a polythene bag.

(7) Vials of eye and ear drops should be packed in an individual carton with a dispensing device. If the vial is of FFS/BFS technology, they should be packed in 50's in a grey board box.

ANNEXURE -XVI

Ref. clause 16.2

MANDATE FORM

Sl.No.	Details Required	
1.	**Company Name**	
2.	Postal Address of the Company	
	Telephone No.	
	Fax No.	
	E-mail ID	
3.	Name of the Managing Director / Director / Manager	
	Mobile No. / Phone No	
	E-mail ID	
4.	Name and Designation of the authorized company official	Name:
		Designation:
	Mobile No.	
	E-mail ID	
5.	**Bank Details**	
	a) Name of the Bank	
	b) Branch Name & address	
	c) Branch Code No.	
	d) Branch Manager Mobile No.	
	e) Branch Telephone no	
	f) Branch E-mail ID	
	g) 9 digit MICR code number of the bank and branch appearing on the MICR cheque issued by the bank	
	h) IFSC Code of the Branch	
	i) Type of Account (Current / Savings)	
	j) Account Number (as appear in cheque book)	

(In lieu of the bank certificate to be obtained, please **attach the original cancelled cheque** issued by your bank for verification of the above particulars).

I / We hereby declare that the particulars given above are correct and complete. If the transaction is delayed or not effected at all the reasons of incomplete or incorrect information, I would not hold Bureau of Pharma Public Sector Undertakings of India (BPPI) responsible.

I have read the conditions of the tender / agreement entered and agree to discharge the responsibility expected of me / from the company as a tenderer / successful tenderer.

Date: Company Seal Signature

Place: (Name of the person signing & designation)

CERTIFIED THAT THE PARTICULARS FURNISHED ABOVE BY THE COMPANY ARE CORRECT AS PER OUR RECORDS.

Signature of the authorized official of the bank

Bank Seal with address:

Annexure - XVII

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKING OF INDIA,GURGAON

TENDER FOR THE SUPPLY OF MEDICINES REFERENCE BPPI/DRUGS-29/2015 Dt 22/09/2015

Landed Price

Note: *For combination drugs which are not official in the Pharmacopoeias, the manufacturer will have to Provide the test Protocol.

**as per stated formulation /Combination is fixed but strength may very

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Approx. tender Quantity in units	Manufacturing capacity per year in units	Rate per unit Landed Price inclusive of Packing & forwarding charges, freight, delivery and Insurance but exclusive of CST and central excise duty in ₹)	Total value (5x7) in figures in ₹	Rate of CST in % against form 'C'	Cen. Excise duty applicable (Yes/ No)
(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)
1	14	IBUPROFEN 400 MG + PARACETAMOL 325 MG	15's						
2	15	IBUPROFEN 200MG FILM COATED	10x10						
3	16	IBUPROFEN 400 MG	15's						
4	89	CO-TRIMOXAZOLE TABLETS IP (160 MG + 800 MG)	10's						
5	165	CIPROFLOXACIN INJECTION IP 2MG/ML	100 ml						
6	191	FAMOTIDINE TABLETS IP 20 MG	14's						
7	194	HYOSCINE 10 MG	10's						
8	201	METRONIDAZOLE 200 MG FILM COATED	10's						

Annexure - XVII

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKING OF INDIA,GURGAON

TENDER FOR THE SUPPLY OF MEDICINES REFERENCE BPPI/DRUGS-29/2015 Dt 22/09/2015

Landed Price

Note: *For combination drugs which are not official in the Pharmacopoeias, the manufacturer will have to Provide the test Protocol.

**as per stated formulation /Combination is fixed but strength may very

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Approx. tender Quantity in units	Manufacturing capacity per year in units	Rate per unit Landed Price inclusive of Packing & forwarding charges, freight, delivery and Insurance but exclusive of CST and central excise duty in ₹)	Total value (5x7) in figures in ₹	Rate of CST in % against form 'C'	Cen. Excise duty applicable (Yes/ No)
(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)
9	202	METRONIDAZOLE 400 MG	10's						
10	255	SALBUTAMOL INHALATION IP 100 µg 200 MD	1's						
11	256	SALBUTAMOL 2 MG	10's						
12	329	PREDNISOLONE TABLETS IP 5 MG	15's						
13	333	DEXAMETHASONE 0.5 MG TABS	10's						
14	334	DEXAMETHASONE INJECTION IP 4 MG/ML	2ML						

Annexure - XVII

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKING OF INDIA,GURGAON

TENDER FOR THE SUPPLY OF MEDICINES REFERENCE BPPI/DRUGS-29/2015 Dt 22/09/2015

Landed Price

Note: *For combination drugs which are not official in the Pharmacopoeias, the manufacturer will have to Provide the test Protocol.

**as per stated formulation /Combination is fixed but strength may very

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Approx. tender Quantity in units	Manufacturing capacity per year in units	Rate per unit Landed Price inclusive of Packing & forwarding charges, freight, delivery and Insurance but exclusive of CST and central excise duty in ₹)	Total value (5x7) in figures in ₹	Rate of CST in % against form 'C'	Cen. Excise duty applicable (Yes/ No)
(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)
15	345	GENTAMYCIN 0.3% W/V	5ML						
16	392	GRISEOFULVIN TABLETS IP 250 MG	10's						
17	408	BENZYLPENICILLIN INJ IP 0.6 MILLION UNITS	VIAL						
18	409	BENZYLPENICILLIN INJ IP 1.2 MILLION UNITS	VIAL						
19	492	SULFASALAZINE TABLETS EC BP 500 MG	10's						
20	514	CHYMOTRYPSIN + TRYPSIN (1:6) TABLETS 100K AU	20's						

Annexure - XVII

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKING OF INDIA,GURGAON

TENDER FOR THE SUPPLY OF MEDICINES REFERENCE BPPI/DRUGS-29/2015 Dt 22/09/2015

Landed Price

Note: *For combination drugs which are not official in the Pharmacopoeias, the manufacturer will have to Provide the test Protocol.

**as per stated formulation /Combination is fixed but strength may very

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Approx. tender Quantity in units	Manufacturing capacity per year in units	Rate per unit Landed Price inclusive of Packing & forwarding charges, freight, delivery and Insurance but exclusive of CST and central excise duty in ₹)	Total value (5x7) in figures in ₹	Rate of CST in % against form 'C'	Cen. Excise duty applicable (Yes/ No)
(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)
21	600	Paracetamol IP…170 mg. Phenylephrine Hydrochloride IP…2.5 mg., Dextromethorphan Hydrochloride IP…5 mg., Chlorpheniramine Maleate IP…1.5 mg. In a flavoured syrupy base…q.s.	60 ml.						
22	601	Disulfiram IP 500 mg	4s						
23	602	Cold & Flu Tab N/F (Nimesulide 100 mg Paracetamool 500 mg Cetirizine Hydrochloride 5 mg Phenylephrine Hydrochloride 5 mg Caffeine (Anhydrous) 25 mg	10's						
24	603	Cetirizine Dihydrochloride IP…5 mg., Phenylephrine Hydrochloride IP…10 mg., Paracetamol IP…325 mg.	10s						
25	604	Levocetrizine HCL 5mg, Phenylephrine HCL 5mg, Ambroxol HCL 30mg, Paracetamol 325mg	10's						
26	605	Etofylline BP…..200 mg., Salbutamol Sulphate IP equivalent to Salbutamol .4 mg, Bromhexine Hydrochloride IP…..8 mg.	10s						

Annexure - XVII

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKING OF INDIA,GURGAON

TENDER FOR THE SUPPLY OF MEDICINES REFERENCE BPPI/DRUGS-29/2015 Dt 22/09/2015

Landed Price

Note: *For combination drugs which are not official in the Pharmacopoeias, the manufacturer will have to Provide the test Protocol.

**as per stated formulation /Combination is fixed but strength may very

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Approx. tender Quantity in units	Manufacturing capacity per year in units	Rate per unit Landed Price inclusive of Packing & forwarding charges, freight, delivery and Insurance but exclusive of CST and central excise duty in ₹)	Total value (5x7) in figures in ₹	Rate of CST in % against form 'C'	Cen. Excise duty applicable (Yes/ No)
(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)
27	606	Cyproheptadine 4 mg	10's						
28	607	Beclamethasone Dipropionate..0.025% w/, Neomycin Sxulphate..0.5% w/w (3500 Unit /G) Chlorocresol 0.1% w/w	15 gms.						
29	608	Betamethasone 0.05% w/w + Salicylic acid 3% w/w	20 Gm						
30	609	Silver Nitrate 0.20 % w/w, Chlorhexidine Gluconate Solution 0.20%, Preservative: Chlorocresol 0.12 % w/w, In a Cream Base q.s.	15 Gms Tube						
31	610	Cold Suspn.N/F (Paracetamol 125 mg+ Phenylephrine Hydrocloride IP 5mg + Cetirizine Dihydrocloride IP 2mg syrup	60ml						
32	611	Cyproheptadine, Hydrochloride(anhydrous) IP..2 mg.In a flavoured syrup base ….q.s.	200 ml.						

Annexure - XVII

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKING OF INDIA,GURGAON

TENDER FOR THE SUPPLY OF MEDICINES REFERENCE BPPI/DRUGS-29/2015 Dt 22/09/2015

Landed Price

Note: *For combination drugs which are not official in the Pharmacopoeias, the manufacturer will have to Provide the test Protocol.

**as per stated formulation /Combination is fixed but strength may very

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Approx. tender Quantity in units	Manufacturing capacity per year in units	Rate per unit Landed Price inclusive of Packing & forwarding charges, freight, delivery and Insurance but exclusive of CST and central excise duty in ₹)	Total value (5x7) in figures in ₹	Rate of CST in % against form 'C'	Cen. Excise duty applicable (Yes/ No)
(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)
33	612	Dusting Powder (Povidone 5% Powder	10 Gm Container						
34	613	Diclofenac Potassium BP 50 mg + Paracetamol 325 mg + Serratiopeptidase 10 mg	10's						
35	614	Ear Drops (Paradichlorobenzene 2%+Benzocaine 2.7%+Chlorbutol 5%+Turpentine Oil15%	10ml						
36	615	Clobetasol Propionate USP…0.05 % w/w, Neomycin Sulphate IP equivalent to Neomycin…0.5 % w/w, Miconazole Nitrate IP…2.0 % ww, Zinc Sulphate IP…2.0 % w/w.	10 gms.						
37	616	Celecoxib 100 mg capsules	10's						
38	617	Celecoxib 200 mg capsules	10's						

Annexure - XVII

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKING OF INDIA,GURGAON

TENDER FOR THE SUPPLY OF MEDICINES REFERENCE BPPI/DRUGS-29/2015 Dt 22/09/2015

Landed Price

Note: *For combination drugs which are not official in the Pharmacopoeias, the manufacturer will have to Provide the test Protocol.

**as per stated formulation /Combination is fixed but strength may very

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Approx. tender Quantity in units	Manufacturing capacity per year in units	Rate per unit Landed Price inclusive of Packing & forwarding charges, freight, delivery and Insurance but exclusive of CST and central excise duty in ₹)	Total value (5x7) in figures in ₹	Rate of CST in % against form 'C'	Cen. Excise duty applicable (Yes/ No)
(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)
39	618	Paracetamol IP 450mg Bromhexine Hydrochloride 8mg Chlorpheniramine maleate 2mg Phenylephrine Hydrochloride 10mg Guaiphenesin 100mg	10's						
40	619	Cough Paed. Syrup Dextromethorphan Hydrobromide IP 5 mg. + Bromhexine HCl 4mg+ Phenylpropanolamine HCl 10 mg+ Menthol IP 0.75 mg / 5ml	60 ml Bottle						
41	620	BromhexineHCl+ Dextrometh orphan +Ammonium Chloride+Menthol	100ml Bottle						
42	621	Iron & Zinc (Carbonyl Iron 50 mg+ Zinc Sulphate Monohydrate USP 61.8 mg equivalent to Elemental Zinc 22.5 mg + Folic Acid IP 0.5mg	15's						
43	622	Cough lozenges Ginger / Lemon (2,4 Diclorobenzyl alcohol1.2 mg + Amylmetacresol 0.6 mg in Ginger /Lemon flavour	8's						
44	623	Cough lozenges Regular 2,4 - Diclorobenzyl Alcohol 1.2 mg, Amylmetacresol BP 0.6 mg	8's						

Annexure - XVII

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKING OF INDIA,GURGAON

TENDER FOR THE SUPPLY OF MEDICINES REFERENCE BPPI/DRUGS-29/2015 Dt 22/09/2015

Landed Price

Note: *For combination drugs which are not official in the Pharmacopoeias, the manufacturer will have to Provide the test Protocol.

**as per stated formulation /Combination is fixed but strength may very

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Approx. tender Quantity in units	Manufacturing capacity per year in units	Rate per unit Landed Price inclusive of Packing & forwarding charges, freight, delivery and Insurance but exclusive of CST and central excise duty in ₹)	Total value (5x7) in figures in ₹	Rate of CST in % against form 'C'	Cen. Excise duty applicable (Yes/ No)
(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)
45	624	Cough Expectorant Chlorpheniramine Maleate 2.5 mg + Ammonium chloride 125mg + Sodium Citrate 55mg	100ml Bottle						
46	625	Cough Tablets Bromhexine Hydrochloride 8.00 mg Phenylephrine Hydrochloride 5.00 mg	15's						
47	626	Dandruf Shampoo KETOCONAZOLE IP SHAMPOO 1% W/V	100ml Bottle						
48	627	Etophylline IP 115mg + Theophylline 35mg	10's						
49	628	Etophylline IP 231mg. + Theophylline 69mg	10's						
50	629	Inhalent Softgel Caps. (Camphor 25 mg + Clorothymol 5 mg + Eucalyptus 130 mg + Menthol 55 mg + Turpentine oil 110 mg	10's						

Annexure - XVII

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKING OF INDIA,GURGAON

TENDER FOR THE SUPPLY OF MEDICINES REFERENCE BPPI/DRUGS-29/2015 Dt 22/09/2015

Landed Price

Note: *For combination drugs which are not official in the Pharmacopoeias, the manufacturer will have to Provide the test Protocol.

**as per stated formulation /Combination is fixed but strength may very

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Approx. tender Quantity in units	Manufacturing capacity per year in units	Rate per unit Landed Price inclusive of Packing & forwarding charges, freight, delivery and Insurance but exclusive of CST and central excise duty in ₹)	Total value (5x7) in figures in ₹	Rate of CST in % against form 'C'	Cen. Excise duty applicable (Yes/ No)
(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)
51	630	laxative Suspension Liqid Paraffin 3.75ml+Milk of Magnesia 11.25ml)	170ml Bottle						
52	631	Ethamsylate B.P 500 mg.	10's						
53	632	Ethamsylate B.P 250 mg.	10's						
54	633	Anti-acne Gel Adapalene BP…0.1 % w/w, Clindamycin Phosphate USP equivalent to Clindamycin…1% w/w, Methyl Paraben IP…0.1 % w/w, Phenoxyethanol BP…0.25 % w/w	15 gms.Tube						
55	634	Clobetasol Proppionate BP…0.05 % w/w, Neomycin Sulhate IP…0.50 % w/w., Miconazole Nitrate IP…2.00 % w/w, Chlorhexidine Gluconate SolutionIP…0.20 %., Chlorocresol IP(as preservative) 0.10 % w/w	20 gms.						
56	635	Clobetasol Propionate BP…0.05% w/w, Neomycin Sulphate IP …0.50% w/w.Miconazole Nitrate IP….2.00% w/w, Chlorhexidine Gluconate Solution…..0.20%, Chlorocresol IP (as preservative) 0.10% w/w	10 gms tube						

Annexure - XVII

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKING OF INDIA,GURGAON

TENDER FOR THE SUPPLY OF MEDICINES REFERENCE BPPI/DRUGS-29/2015 Dt 22/09/2015

Landed Price

Note: *For combination drugs which are not official in the Pharmacopoeias, the manufacturer will have to Provide the test Protocol.

**as per stated formulation /Combination is fixed but strength may very

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Approx. tender Quantity in units	Manufacturing capacity per year in units	Rate per unit Landed Price inclusive of Packing & forwarding charges, freight, delivery and Insurance but exclusive of CST and central excise duty in ₹)	Total value (5x7) in figures in ₹	Rate of CST in % against form 'C'	Cen. Excise duty applicable (Yes/ No)
(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)
57	636	Ferric Ammonium Citrate 200 mg, Cyanocobalamin 7.5 mcg, Folic acid 0.5 mg, Zinc Sulphate 7 mg, Pyridoxine Hcl 1.5 mg, Sorbitol 70%	225 ml						
58	637	Aceclofenac 100 mg + Paracetamol 325 mg + Chorzoxazone 250 mg film coated tab.	10's						
59	638	Aceclofenac 100 mg Paracetamol 325 mg Serratiopeptidase 15 mg	10's						
60	639	Mucodilator Expectorant Terbutaline Sulphate 1.25 mg, Bromhexine 4 mg, Guaiphenesin 50 mg, Menthol 2.5 mg per 5 ml	100 ml						
61	640	Nimesulide 1% W/W Gel	20 Gm tube						
62	642	Triprolidine Hydrochloride 2.5mg Phenylephrine Hydrochloride 10mg Paracetamol 500 mg	10'S						

Annexure - XVII

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKING OF INDIA,GURGAON

TENDER FOR THE SUPPLY OF MEDICINES REFERENCE BPPI/DRUGS-29/2015 Dt 22/09/2015

Landed Price

Note: *For combination drugs which are not official in the Pharmacopoeias, the manufacturer will have to Provide the test Protocol.

**as per stated formulation /Combination is fixed but strength may very

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Approx. tender Quantity in units	Manufacturing capacity per year in units	Rate per unit Landed Price inclusive of Packing & forwarding charges, freight, delivery and Insurance but exclusive of CST and central excise duty in ₹)	Total value (5x7) in figures in ₹	Rate of CST in % against form 'C'	Cen. Excise duty applicable (Yes/ No)
(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)
63	643	Paracetamol 125mg+ CPM 1 mg + Sodium Citrate 60mg in a flavour syrup base	60 ml Bottle						
64	644	Phenylephrine Hydrochloride 5.00mg Chlorpheniranmine Maleate 2.00mg	15ml Bottle						
65	645	Nimesulide 100mg, Paracetamol 325mg, Chlorzoxazone 375mg	10's						
66	646	Diclofenac diethylamine BP 1.116% (equivalent to diclofenac sodium 1.0%, Linseed oil BP 3.0% + Methyl Salicylate IP 10.0%, Capsiacin USP 0.025%, Menthol IP 0.025%, Benzyl alcohol IP 1.0% (as preservative) In a gel base q.s.	30 Gm						
67	647	Diclofenac Di + Menthol 5%+ Oleum 3% + Methyl Salicylate	20 Gm						
68	648	Dethylamine BP…1.16 %, Linseed Oil BP…3 % w/w, Methyl Salicylate IP…10 % w/w, Menthol IP…5 % w/w, Excipients and Propellant q.s. to…100 % w/w	35 gms.						

Annexure - XVII

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKING OF INDIA,GURGAON

TENDER FOR THE SUPPLY OF MEDICINES REFERENCE BPPI/DRUGS-29/2015 Dt 22/09/2015

Landed Price

Note: *For combination drugs which are not official in the Pharmacopoeias, the manufacturer will have to Provide the test Protocol.

**as per stated formulation /Combination is fixed but strength may very

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Approx. tender Quantity in units	Manufacturing capacity per year in units	Rate per unit Landed Price inclusive of Packing & forwarding charges, freight, delivery and Insurance but exclusive of CST and central excise duty in ₹)	Total value (5x7) in figures in ₹	Rate of CST in % against form 'C'	Cen. Excise duty applicable (Yes/ No)
(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)
69	649	Dicyclomine 10mg + Act. Dimethicone 40mg per ml	10ml Bottle						
70	650	Mefenamic Acid 500mg+Paracetamol 450 mg	10's						
71	651	Paracetamol IP…125 mg., Mefanamic Acid IP…50 mg., in a flavoured syrupy base…q.s.	60 ml.						
72	652	Dicyclomine 10mg + Mefenamic 250 mg	10's						
73	653	Syrup Vitamin D3 200 IU + Vitamin B12 2.5 mcg + Calcium Phosphate eq. to elemental Calcium 82 mg / 5 ml	225 ml						
74	654	Enyme Syrup Cardamom Flavour Pepsin 7.5 mg + Fungal Diastase 12.5 mg / 5 ml	200 ml						

Annexure - XVII

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKING OF INDIA,GURGAON

TENDER FOR THE SUPPLY OF MEDICINES REFERENCE BPPI/DRUGS-29/2015 Dt 22/09/2015

Landed Price

Note: *For combination drugs which are not official in the Pharmacopoeias, the manufacturer will have to Provide the test Protocol.

**as per stated formulation /Combination is fixed but strength may very

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Approx. tender Quantity in units	Manufacturing capacity per year in units	Rate per unit Landed Price inclusive of Packing & forwarding charges, freight, delivery and Insurance but exclusive of CST and central excise duty in ₹)	Total value (5x7) in figures in ₹	Rate of CST in % against form 'C'	Cen. Excise duty applicable (Yes/ No)
(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)
75	655	Enyme Syrup Mix Fruit Flavour Pepsin 7.5 mg + Fungal Diastase 12.5 mg / 5 ml	200 ml						
76	656	Enzyme Drops Pepsin (1:3000) 5 mg + Fungal Diastase (1:1200) 33.33 mg/ml	15ML						
77	657	Hydroquinone 2.0% w/w + Tretinoin 0.025% w/w + Mometasone Furoate 0.1% w/w in a cream base q.s	15 gm						
78	658	Chlorhexidine Gluconate 0.3% v/v + Cetrimide 0.6% w/v	100 ml						
79	659	Chlorhexidine Gluconate 0.3% v/v + Cetrimide 0.6% w/v	200 ml						
80	660	Cetrimide 0.5% + Vit. E Acetate 0.1% + Glycerin q.s	75 gms.						

Annexure - XVII

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKING OF INDIA,GURGAON

TENDER FOR THE SUPPLY OF MEDICINES REFERENCE BPPI/DRUGS-29/2015 Dt 22/09/2015

Landed Price

Note: *For combination drugs which are not official in the Pharmacopoeias, the manufacturer will have to Provide the test Protocol.

**as per stated formulation /Combination is fixed but strength may very

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Approx. tender Quantity in units	Manufacturing capacity per year in units	Rate per unit Landed Price inclusive of Packing & forwarding charges, freight, delivery and Insurance but exclusive of CST and central excise duty in ₹)	Total value (5x7) in figures in ₹	Rate of CST in % against form 'C'	Cen. Excise duty applicable (Yes/ No)
(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)
81	661	Gama Benzene Hexachloride 1 % w/v + Cetrimide 0.1% w/v	100ml						
82	662	Gama Benzene Hexachloride 1 % w/v + Cetrimide 0.1% w/v	200ML						
83	663	Junior Cough Syrup Chlorpheniramine Maleate 2 mg + Dextromethorphan Hydrobromide 10 mg + Phenylephrine HCl 5 mg / 5 ml	100 ml						
84	664	Mouth Ulcer Gel (Choline Salicylate sodium 9% w/v, Benzalkonium Chloride 0.01% w/w)	10 gm						
85	665	BCOMPLEX PLUS Each capsule contains - Thiamine mononitrate IP-10mg,Riboflavin IP -10 mg,Pyridoxine HCl IP-3mg,Vitamin B 12 IP - 5mcg,Niacimnamide IP -50mg,Calcium Pantothenate IP-12.5mg,Flolic Acid IP - 1mg, Ascorbic Acid IP- 150mg	10's						

Annexure - XVII

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKING OF INDIA,GURGAON

TENDER FOR THE SUPPLY OF MEDICINES REFERENCE BPPI/DRUGS-29/2015 Dt 22/09/2015

Landed Price

Note: *For combination drugs which are not official in the Pharmacopoeias, the manufacturer will have to Provide the test Protocol.

**as per stated formulation /Combination is fixed but strength may very

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Approx. tender Quantity in units	Manufacturing capacity per year in units	Rate per unit Landed Price inclusive of Packing & forwarding charges, freight, delivery and Insurance but exclusive of CST and central excise duty in ₹)	Total value (5x7) in figures in ₹	Rate of CST in % against form 'C'	Cen. Excise duty applicable (Yes/ No)
(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)
86	666	Pheniramine Maleate I.P. 22.75mg,Methyl Paraben(as preservative) I.P. 0.135% w/v, Propyl Paraben(as preservative) I.P. 0.015% w/v, Water for injection I.P. q.s.	2ml						
87	667	Paracetamol I.P. 125 mg: Promethazine HCl I.P. 5 mg	15ml						
88	668	Multivitamin Drops : Vitamin A(as Palmitate)IP 2500 IU, Vitamin E Acetate IP 2.5 IU,Vitamin D3 IP 200 IU,Ascorbic Acid IP 40mgThiamine Hydrochloride IP 1mg,Riboflavine Sodium Phosphate IP 1.5mg,Niacinamide IP 10mg,D-Panthenol IP 3mg,D-Botin BP 50mcg ,Lysine	15ml						
89	669	Syrup - Cefuroxime 125mg(asCefuroxime Axetil USP)	30ml						
90	670	Diacerein 50 mg +Methylsulphonylmethane 200 mg + Glucosamine Sulphate 500 mg	10's						

Annexure - XVII

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKING OF INDIA,GURGAON

TENDER FOR THE SUPPLY OF MEDICINES REFERENCE BPPI/DRUGS-29/2015 Dt 22/09/2015

Landed Price

Note: *For combination drugs which are not official in the Pharmacopoeias, the manufacturer will have to Provide the test Protocol.

**as per stated formulation /Combination is fixed but strength may very

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Approx. tender Quantity in units	Manufacturing capacity per year in units	Rate per unit Landed Price inclusive of Packing & forwarding charges, freight, delivery and Insurance but exclusive of CST and central excise duty in ₹)	Total value (5x7) in figures in ₹	Rate of CST in % against form 'C'	Cen. Excise duty applicable (Yes/ No)
(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)
91	671	Diacerein 50 mg + Glucosamine Sulphate 500 mg	10's						
92	672	Mometasone Furoate 0.1 % w/w	15gm						
93	673	Biotin 10 mg	10's						
94	674	Sitaglptin 100 mg	10's						
95	675	Sitaglptin 50 mg	10's						
96	676	Trimcelone Acetonide 0.1 % Mouth Ulcer gel	10gm						

Annexure - XVII

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKING OF INDIA,GURGAON

TENDER FOR THE SUPPLY OF MEDICINES REFERENCE BPPI/DRUGS-29/2015 Dt 22/09/2015

Landed Price

Note: *For combination drugs which are not official in the Pharmacopoeias, the manufacturer will have to Provide the test Protocol.

**as per stated formulation /Combination is fixed but strength may very

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Approx. tender Quantity in units	Manufacturing capacity per year in units	Rate per unit Landed Price inclusive of Packing & forwarding charges, freight, delivery and Insurance but exclusive of CST and central excise duty in ₹)	Total value (5x7) in figures in ₹	Rate of CST in % against form 'C'	Cen. Excise duty applicable (Yes/ No)
(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)
97	677	Flupentixol 0.5 mg	10's						
98	678	levodopa & Carbidopa tab	10's						
99	679	Nalidixic Acid 500 mg	10's						
100	680	Finaestride 5 mg	10's						
101	681	Phenazopyridine Hcl 100mg tab	10's						
102	682	Rabeprazole 20mg + Domperidone 10mg	10's						

Annexure - XVII

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKING OF INDIA,GURGAON

TENDER FOR THE SUPPLY OF MEDICINES REFERENCE BPPI/DRUGS-29/2015 Dt 22/09/2015

Landed Price

Note: *For combination drugs which are not official in the Pharmacopoeias, the manufacturer will have to Provide the test Protocol.

**as per stated formulation /Combination is fixed but strength may very

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Approx. tender Quantity in units	Manufacturing capacity per year in units	Rate per unit Landed Price inclusive of Packing & forwarding charges, freight, delivery and Insurance but exclusive of CST and central excise duty in ₹)	Total value (5x7) in figures in ₹	Rate of CST in % against form 'C'	Cen. Excise duty applicable (Yes/ No)
(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)
103	683	Rabeprazole Sodium ip 20mg + Itopiride HCL 150mg	10's						
104	684	Pantoprazole 40mg + Domperidone 30mg S.R.	10's						
105	685	Pantoprazole 40mg + Itopride 150mg S.R.	10's						
106	686	Magaldrate 400 mg + Simethiocone 20 mg	170 ml						
107	687	Lactulose 10 gm/ 15 ml	200 ml						
108	688	Nitroglycerine Injection 5mg/ ml	10 ml Vial						

Annexure - XVII

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKING OF INDIA,GURGAON

TENDER FOR THE SUPPLY OF MEDICINES REFERENCE BPPI/DRUGS-29/2015 Dt 22/09/2015

Landed Price

Note: *For combination drugs which are not official in the Pharmacopoeias, the manufacturer will have to Provide the test Protocol.

**as per stated formulation /Combination is fixed but strength may very

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Approx. tender Quantity in units	Manufacturing capacity per year in units	Rate per unit Landed Price inclusive of Packing & forwarding charges, freight, delivery and Insurance but exclusive of CST and central excise duty in ₹)	Total value (5x7) in figures in ₹	Rate of CST in % against form 'C'	Cen. Excise duty applicable (Yes/ No)
(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)
109	689	Clotrimazole 100 mgVaginal Tab	10's						
110	690	Timolol Maeleate 0.5 % Eye Drops	10 ml Vial						
111	691	Ofloxacin Eye Drops	10 ml Vial						
112	692	Olopattadine Eye Drops	10 ml Vial						
113	693	Tropicamide Eye Drops	10 ml Vial						
114	694	Tobramycin Eye Drops	10 ml Vial						

Annexure - XVII

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKING OF INDIA,GURGAON

TENDER FOR THE SUPPLY OF MEDICINES REFERENCE BPPI/DRUGS-29/2015 Dt 22/09/2015

Landed Price

Note: *For combination drugs which are not official in the Pharmacopoeias, the manufacturer will have to Provide the test Protocol.

**as per stated formulation /Combination is fixed but strength may very

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Approx. tender Quantity in units	Manufacturing capacity per year in units	Rate per unit Landed Price inclusive of Packing & forwarding charges, freight, delivery and Insurance but exclusive of CST and central excise duty in ₹)	Total value (5x7) in figures in ₹	Rate of CST in % against form 'C'	Cen. Excise duty applicable (Yes/ No)
(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)
115	695	Polymyxin B sulphate BP 5000 iu , Chloramphenicol IP 4mg Phenulmercuiric intrate IP	5 ml						
116	696	Polymyxin B sulphate BP 5000 iu , Chloramphenicol IP 4mg ,Dexamethasone sodium phosphate IP 1 mg Phenulmercuiric intrate IP	5 ml						
117	697	Sulfacetamide eye drop 10 %	10 ml						
118	698	Sulfacetamide eye drop 20 %	20 ml						
119	699	Acyclovir Eye Ointment	5gm						
120	700	Ketamine Hydrochloride 10 mg/ml Injection	20ml Vial						

Annexure - XVII

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKING OF INDIA,GURGAON

TENDER FOR THE SUPPLY OF MEDICINES REFERENCE BPPI/DRUGS-29/2015 Dt 22/09/2015

Landed Price

Note: *For combination drugs which are not official in the Pharmacopoeias, the manufacturer will have to Provide the test Protocol.

**as per stated formulation /Combination is fixed but strength may very

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Approx. tender Quantity in units	Manufacturing capacity per year in units	Rate per unit Landed Price inclusive of Packing & forwarding charges, freight, delivery and Insurance but exclusive of CST and central excise duty in ₹)	Total value (5x7) in figures in ₹	Rate of CST in % against form 'C'	Cen. Excise duty applicable (Yes/ No)
(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)
121	701	Pilocar 2 % eye drop	10 ml Vial						
122	702	Haloperidol 0.5 mg	10's						
123	703	Nimsulide 100 mg + Serratiopeptidae 15 mg	10's						
124	704	Cephalexin 125mg/5ml dry syrup	30ml						
125	705	Levofloxacin 500 mg INFUSION / IV	100ml						
126	706	Cefpodoxime proxetil 50 mg DS dry syrup	30ml						

Annexure - XVII

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKING OF INDIA,GURGAON

TENDER FOR THE SUPPLY OF MEDICINES REFERENCE BPPI/DRUGS-29/2015 Dt 22/09/2015

Landed Price

Note: *For combination drugs which are not official in the Pharmacopoeias, the manufacturer will have to Provide the test Protocol.

**as per stated formulation /Combination is fixed but strength may very

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Approx. tender Quantity in units	Manufacturing capacity per year in units	Rate per unit Landed Price inclusive of Packing & forwarding charges, freight, delivery and Insurance but exclusive of CST and central excise duty in ₹)	Total value (5x7) in figures in ₹	Rate of CST in % against form 'C'	Cen. Excise duty applicable (Yes/ No)
(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)
127	707	Piroxicam 10 mg tablets	10's						
128	708	Piroxicam 20 mg btablets	10's						
129	709	Piroxicam 20 mg with bezyl alcohol injection	1ml						
130	710	Piroxicam 40 mg with bezyl alcohol injection	2ml						
131	711	Ofloxacin 50mg+Ornidazole125mg+Simethicone 10 mg	60ml						
132	712	Paracetamol DS syrup /250 mg	60ml						

Annexure - XVII

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKING OF INDIA,GURGAON

TENDER FOR THE SUPPLY OF MEDICINES REFERENCE BPPI/DRUGS-29/2015 Dt 22/09/2015

Landed Price

Note: *For combination drugs which are not official in the Pharmacopoeias, the manufacturer will have to Provide the test Protocol.

**as per stated formulation /Combination is fixed but strength may very

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Approx. tender Quantity in units	Manufacturing capacity per year in units	Rate per unit Landed Price inclusive of Packing & forwarding charges, freight, delivery and Insurance but exclusive of CST and central excise duty in ₹)	Total value (5x7) in figures in ₹	Rate of CST in % against form 'C'	Cen. Excise duty applicable (Yes/ No)
(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)
133	713	Glibenclamide 5mg + MetforminHcl 500 mg	10's						
134	714	Ofloxacin 200mg+Ornidazole500mg infusion	100 ml						
135	715	Glycerin ip 98%w/w	50 gm						
136	716	Urea IP 1 % + Salicylic Acid IP 1% w/w Zinc Sulphate 0.1 % w/w	10 gm						
137	717	Etodolac tablets 300 USP mg	10's						
138	718	Escitalopram 10mg with Clonazepam 0.5mg	10's						

Annexure - XVII

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKING OF INDIA,GURGAON

TENDER FOR THE SUPPLY OF MEDICINES REFERENCE BPPI/DRUGS-29/2015 Dt 22/09/2015

Landed Price

Note: *For combination drugs which are not official in the Pharmacopoeias, the manufacturer will have to Provide the test Protocol.

**as per stated formulation /Combination is fixed but strength may very

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Approx. tender Quantity in units	Manufacturing capacity per year in units	Rate per unit Landed Price inclusive of Packing & forwarding charges, freight, delivery and Insurance but exclusive of CST and central excise duty in ₹)	Total value (5x7) in figures in ₹	Rate of CST in % against form 'C'	Cen. Excise duty applicable (Yes/ No)
(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)
139	719	Ringer Lactate IV fluid beg self collapsible closed system	100 ml						
140	720	Ringer Lactate I V fluid beg self collapsible closed system	500ml						
141	721	Water for Injection amp polypack	2ml						
142	722	Water for Injection amp polypack	5ml						
143	723	Water for Injection amp polypack	10ml						
144	724	Whey Peptide based Enteral nutrition Per 100gm Energy 464 Kcal Protin 18.5gm Fat 17 gm MUFA 1.19Gm PUFA 2.58, Carbs 59.40gm Vit A / D/ E/K/C/B1/ B2/NIACIN/B6/Folic Acid/ Pantothenic Acid / B12/ Biotin/ Minerals and Choline Taurine & Carnitine	200 gm Tin						

Annexure - XVII

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKING OF INDIA,GURGAON

TENDER FOR THE SUPPLY OF MEDICINES REFERENCE BPPI/DRUGS-29/2015 Dt 22/09/2015

Landed Price

Note: *For combination drugs which are not official in the Pharmacopoeias, the manufacturer will have to Provide the test Protocol.

**as per stated formulation /Combination is fixed but strength may very

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Approx. tender Quantity in units	Manufacturing capacity per year in units	Rate per unit Landed Price inclusive of Packing & forwarding charges, freight, delivery and Insurance but exclusive of CST and central excise duty in ₹)	Total value (5x7) in figures in ₹	Rate of CST in % against form 'C'	Cen. Excise duty applicable (Yes/ No)
(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)
145	725	Dextrose 5 %	500ml IV fluid beg self collapsible closed system						
146	726	Dextrose 10 %	500ml IV fluid beg self collapsible closed system						
147	727	Dextrose with Saline 5% + 0.45%	500ml IV fluid beg self collapsible closed system						
148	728	Dextrose with Saline 5% + 0.9%	500ml IV fluid beg self collapsible closed system						

Annexure - XVII

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKING OF INDIA,GURGAON

TENDER FOR THE SUPPLY OF MEDICINES REFERENCE BPPI/DRUGS-29/2015 Dt 22/09/2015

Landed Price

Note: *For combination drugs which are not official in the Pharmacopoeias, the manufacturer will have to Provide the test Protocol.

**as per stated formulation /Combination is fixed but strength may very

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Approx. tender Quantity in units	Manufacturing capacity per year in units	Rate per unit Landed Price inclusive of Packing & forwarding charges, freight, delivery and Insurance but exclusive of CST and central excise duty in ₹)	Total value (5x7) in figures in ₹	Rate of CST in % against form 'C'	Cen. Excise duty applicable (Yes/ No)
(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)
149	729	Dextrose with Saline 5% + 0.22%	500ml I V fluid beg self collapsible closed system						
150	730	Dextrose with Saline (N/2 DNS 5% + 0.45%	500ml IV fluid glass/ plastic container						
151	731	Dextrose with Saline (N/4 DNS) 5% + 0.22%	500ml IV fluid glass/ plastic container						
152	732	Normal Saline (NS) 0.9% w/v	500ml IV fluid glass/ plastic container						